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A B S T R A C T
Background
Down’s syndrome occurs when a person has three copies of chromosome 21 - or the speciﬁc area of chromosome 21 implicated in
causing Down’s syndrome - rather than two. It is the commonest congenital cause of mental retardation. Noninvasive screening based
on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being
affected and provides information to guide decisions about deﬁnitive testing.
Objectives
To estimate and compare the accuracy of second trimester serum markers for the detection of Down’s syndrome.
Search methods
We carried out a sensitive and comprehensive literature search of MEDLINE (1980 to May 2007), EMBASE (1980 to 18 May 2007),
BIOSIS via EDINA (1985 to 18 May 2007), CINAHL via OVID (1982 to 18 May 2007), The Database of Abstracts of Reviews of
Effectiveness (The Cochrane Library 2007, Issue 1), MEDION (May 2007), The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (May 2007), The National Research Register (May 2007), Health Services Research Projects in Progress database
(May 2007). We studied reference lists and published review articles.
Selection criteria
Studies evaluating tests of maternal serum in women at 14-24 weeks of gestation for Down’s syndrome, compared with a reference
standard, either chromosomal veriﬁcation or macroscopic postnatal inspection.
Data collection and analysis
Data were extracted as test positive/test negative results for Down’s and non-Down’s pregnancies allowing estimation of detection
rates (sensitivity) and false positive rates (1-speciﬁcity). We performed quality assessment according to QUADAS criteria. We used
hierarchical summary ROCmeta-analytical methods to analyse test performance and compare test accuracy. Analysis of studies allowing
direct comparison between tests was undertaken. We investigated the impact of maternal age on test performance in subgroup analyses.
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Main results
Fifty-nine studies involving 341,261 pregnancies (including 1,994 with Down’s syndrome) were included. Studies were generally high
quality, although differential veriﬁcation was common with invasive testing of only high-risk pregnancies. Seventeen studies made direct
comparisons between tests. Fifty-four test combinations were evaluated formed from combinations of 12 different tests and maternal
age; alpha-fetoprotein (AFP), unconjugated oestriol (uE3), total human chorionic gonadotrophin (hCG), free beta human chorionic
gonadotrophin (βhCG), free alpha human chorionic gonadotrophin (αhCG), Inhibin A, SP2, CA125, troponin, pregnancy-associated
plasma protein A (PAPP-A), placental growth factor (PGF) and proform of eosinophil major basic protein (ProMBP).
Meta-analysis of 12 best performing or frequently evaluated test combinations showed double and triple tests (involving AFP, uE3, total
hCG, free βhCG) signiﬁcantly outperform individual markers, detecting six to seven out of every 10 Down’s syndrome pregnancies
at a 5% false positive rate. Tests additionally involving inhibin performed best (eight out of every 10 Down’s syndrome pregnancies)
but were not shown to be signiﬁcantly better than standard triple tests in direct comparisons. Signiﬁcantly lower sensitivity occurred
in women over the age of 35 years. Women who miscarried in the over 35 group were more likely to have been offered an invasive test
to verify a negative screening results, whereas those under 35 were usually not offered invasive testing for a negative screening result.
Pregnancy loss in women under 35 therefore leads to under ascertainment of screening results, potentially missing a proportion of
affected pregnancies and affecting the accuracy of the sensitivity.
Authors’ conclusions
Tests involving two or more markers in combination with maternal age are signiﬁcantly more sensitive than those involving one marker.
The value of combining four or more tests or including inhibin have not been proven to show statistically signiﬁcant improvement.
Further study is required to investigate reduced test performance in women aged over 35 and the impact of differential pregnancy loss
on study ﬁndings.
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B A C K G R O U N D
This is one of a series of reviews on antenatal screening for
Down’s syndrome following a generic protocol (Alldred 2010) -
see Published notes for more details.
Target condition being diagnosed
Down’s syndrome
Down’s syndrome affects approximately 1 in 800 live-born babies
(Cuckle 1987a). It results from a person having three, rather than
two, copies of chromosome 21 - or the speciﬁc area of chromosome
21 implicated in causing Down’s syndrome - as a result of trisomy
or translocation. If not all cells are affected, the pattern is described
as ’mosaic’. Down’s syndrome can cause a wide range of physical
and mental problems. It is the commonest cause of mental retar-
dation, and is also associated with a number of congenital malfor-
mations, notably affecting the heart. There is also an increased risk
of cancers such as leukaemia, and numerous metabolic problems
including diabetes and thyroid disease. Some of these problems
may be life threatening, or lead to considerable ill health, while
some individuals with Down’s syndrome have only mild problems
and can lead a relatively normal life.
There is no cure for Down’s syndrome, and antenatal diagnosis
allows for preparation for the birth and subsequent care of a baby
with Down’s syndrome, or for the offer of a termination of preg-
nancy. Having a baby with Down’s syndrome is likely to have a
signiﬁcant impact on family and social life, relationships and par-
ents’ work. Special provisions may need to be made for education
and care of the child, as well as accommodating the possibility of
periods of hospitalisation.
Deﬁnitive invasive tests (amniocentesis and chorionic villus sam-
pling (CVS)) exist that allow the diagnosis of Down’s syndrome
before birth but carry a risk of miscarriage. No test can predict the
severity of problems a person with Down’s syndrome will have.
Noninvasive screening tests based on biochemical analysis of ma-
ternal serum or urine, or fetal ultrasound measurements, allow
an estimate of the risk of a pregnancy being affected and provide
parents with information to enable them to make choices about
deﬁnitive testing. Such screening tests are used during the ﬁrst and
second trimester of pregnancy.
Initially, screening was determined solely by using maternal age to
classify a pregnancy as high or low risk for trisomy 21, as it was
known that older women had a higher chance of carrying a baby
with Down’s syndrome (Penrose 1933).
Further advances in screening were made in the early 1980s, when
Merkatz et al investigated the possibility that low maternal serum
alpha-fetoprotein (AFP), obtained frommaternal blood in the sec-
ond trimester of pregnancy could be associated with chromoso-
mal abnormalities in the fetus. Their retrospective case-control
study showed a statistically signiﬁcant relationship between fetal
trisomy, such as Down’s syndrome, and lowered maternal serum
AFP (Merkatz 1984). This was further explored by Cuckle et al in
a larger retrospective trial using data collected as part of a neural
tube defect (NTD) screening project (Cuckle 1984). This work
was followed by calculation of risk estimates using maternal serum
AFP values and maternal age, which ultimately led to the intro-
duction of the two screening parameters in combination (Alﬁrevic
2004).
In 1987 in a small case-control study of women carrying fe-
tuses with known chromosomal abnormalities, Bogart and col-
leagues investigated maternal serum levels of human chorionic go-
nadotrophin (hCG) as a possible screening tool for chromosomal
abnormalities in the second trimester (Bogart 1987). This fol-
lowed the observations that low hCG levels were associated with
miscarriages, which are commonly associated with fetal chromo-
somal abnormalities. They concluded that high hCG levels were
associated with Down’s syndrome and because hCG levels plateau
at 18-24 weeks, that this would be the most appropriate time for
screening. Later work suggested that the ß sub-unit of hCG was a
more effective marker than total hCG (Macri 1990; Macri 1993).
Second trimester unconjugated oestriol (uE3), produced by the
fetal adrenals and the placenta, was also evaluated as a potential
screening marker. In another retrospective case-control study, uE3
was shown to be lower in Down’s syndrome pregnancies compared
with unaffected pregnancies.Whenused in combinationwithAFP
andmaternal age, it appeared to identifymore pregnancies affected
by Down’s syndrome than AFP and age alone (Canick 1988).
Further work suggested that all three serum markers (AFP, hCG
and uE3) showed even higher detection rates when combined with
maternal age (Wald 1988a; Wald 1988b) and appeared to be a
cost-effective screening strategy (Wald 1992a).
Two other serum markers, produced by the placenta, have
been linked with Down’s syndrome, namely pregnancy-associ-
ated plasma protein A or PAPP-A, and Inhibin A. PAPP-A has
been shown to be reduced in the ﬁrst trimester of Down’s syn-
drome pregnancies, with its most marked reduction in the early
ﬁrst trimester (Bersinger 1995). Inhibin A is high in the second
trimester in pregnancies affected by Down’s syndrome (Cuckle
1995; Wallace 1995). There are some issues concerning the bio-
logical stability and hence reliability of this marker, and the effect
this will have on individual risk.
Antenatal screening is used for several reasons (Alﬁrevic 2004), but
the most important is to enable parental choice regarding preg-
nancy management and outcome. Before a woman and her part-
ner opt to have a screening test, they need to be fully informed
about the risks, beneﬁts and possible consequences of such a test.
This includes the choices they may have to face should the re-
sult show that the woman has a high risk of carrying a baby with
Down’s syndrome and implications of both false positive and false
negative screening tests. They need to be informed of the risk of a
miscarriage due to invasive diagnostic testing, and the possibility
that a miscarried fetus may be chromosomally normal. If, follow-
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ing invasive diagnostic testing, the fetus is shown to have Down’s
syndrome, further decisions need to be made about continuation
or termination of the pregnancy, the possibility of adoption and
ﬁnally, preparation for parenthood. Equally, if a woman has a test
that shows she is at a low risk of carrying a fetus with Down’s
syndrome, it does not necessarily mean that the baby will be born
with a normal chromosomal make up. This possibility can only be
excluded by an invasive diagnostic test (Alﬁrevic 2003).The deci-
sions that may be faced by expectant parents inevitably engender
a high level of anxiety at all stages of the screening process, and the
outcomes of screening can be associated with considerable physi-
cal and psychological morbidity.
Index test(s)
This review examines serum screening tests used in the second
trimester of pregnancy (14 to 24 weeks gestation) comprised of the
following individual markers; Alpha feto-protein (AFP), uncon-
jugated oestriol (uE3), total human chorionic gonadotropin (total
hCG), free ß human chorionic gonadotropin (freeβ hCG), free al-
pha human chorionic gonadotropin (freeα hCG), InhibinA, SP2,
CA125, troponin, pregnancy-associated plasma protein A (PAPP-
A), placental growth factor (PGF), and proform of eosinophil ma-
jor basic protein (ProMBP). These markers can be used individu-
ally, in combination with age, and can also be used in combination
with each other. The risks are calculated by comparing a woman’s
test result for each marker with values for an unaffected popula-
tion, and multiplying this with her age-related risk. Where several
markers are combined, risks are computed using risk equations (of-
ten implemented in commercial software) that take into account
the correlational relationships between the different markers and
marker distributions in affected and unaffected populations.
Alternative test(s)
Down’s syndrome can be detected during pregnancy with invasive
diagnostic tests such as amniocentesis or CVS, with or without
prior screening. These tests are considered to be reference tests
rather than index or screening tests. The ability to determine fetal
chromosomal make up (also known as a karyotype) from amniotic
ﬂuid samples was demonstrated in 1966 by Steele and Breg (Steele
1966), and the ﬁrst antenatal diagnosis of Down’s syndrome was
made in 1968 (Vaklenti 1968). Amniocentesis is an invasive pro-
cedure which involves taking a small sample of the amniotic ﬂuid
(liquor) surrounding the baby, using a needle which goes through
the abdominal wall into the uterus, and is usually performed after
15 weeks gestation. Chorionic Villus Sampling involves taking a
sample of the placental tissue using a needle which goes through
the abdominal wall and uterus or a cannula through the cervix.
It is usually performed between 10 and 13 weeks gestation. Am-
niocentesis and CVS are both methods of obtaining fetal chromo-
somes material which are then used to diagnose Down’s syndrome.
Both tests use ultrasound scans to guide placement of the needle.
Amniocentesis carries a risk of miscarriage in the order of 1%;
transabdominal CVS may carry a similar risk (Alﬁrevic 2003).
There aremany different screening tests which are available and of-
feredwhichwill be the subject of additionalCochrane reviews (cur-
rently in preparation) and there are other reviews looking at this
area. Tests to be assessed inCochrane reviews include ﬁrst trimester
serum tests; urine tests; ﬁrst trimester ultrasound markers; tests
that involve combine serum and ultrasoundmarkers; and tests that
combine markers from the ﬁrst trimester with markers from the
second trimester. Second trimester ultrasound markers have been
assessed in a previous systematic review (Smith-Bindman 2001).
Rationale
This is one of a suite of Cochrane reviews, the aim of which is to
identify all screening tests for Down’s syndrome used in clinical
practice, or evaluated in the research setting, in order to try to iden-
tify the most accurate test(s) available, and to provide clinicians,
policy-makers and women with robust and balanced evidence on
which to base decisions about interpreting test results and imple-
menting screening policies to triage the use of invasive diagnostic
testing. The full set of reviews is described in the generic protocol
(Alldred 2010).
The topic has been split into several different reviews to allow for
greater ease of reading and greater accessibility of data, and also to
allow the reader to focus on separate groups of tests, for example,
ﬁrst trimester serum tests alone, ﬁrst trimester ultrasound alone,
ﬁrst trimester serumandultrasound, second trimester serumalone,
ﬁrst and second trimester serum, combinations of serum and ul-
trasound markers and urine markers alone. An overview review
will compare the best tests, focusing on commonly used strategies,
from each of these groups to give an comparative results between
the best tests in the different categories. This review is written with
the global perspective in mind, rather than to conform with any
speciﬁc local or national policy, as not all tests will be available in
all areas where screening for Down’s syndrome is carried out.
A systematic review of second trimester ultrasound markers in
the detection of Down’s syndrome fetuses was published in 2001
which concluded that nuchal fold thickening may be useful in
detecting Down’s syndrome, but that it was not sensitive enough
to use as a screening test. The review concluded that the other
second trimester ultrasound markers did not usefully distinguish
between Down’s syndrome and pregnancies without Down’s syn-
drome (Smith-Bindman 2001). There has yet to be a systematic
review and meta-analysis of the observed data on serum, urine
and ﬁrst trimester ultrasound markers, in order to draw rigorous
and robust conclusions about the diagnostic accuracy of available
Down’s syndrome screening tests.
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O B J E C T I V E S
The aim of this review was to estimate and compare the accuracy
of second trimester serum markers for the detection of Down’s
syndrome in the antenatal period, both as individual markers and
as combinations of markers. Accuracy is described by the pro-
portion of fetuses with Down’s syndrome detected by screening
before birth (sensitivity or detection rate) and the proportion of
women with a low risk (normal) screening test result who subse-
quently had a baby unaffected by Down’s syndrome (speciﬁcity).
We grouped our analyses to focus on investigating the value of
adding increasing numbers of markers (comparing single, dual,
triple and quadruple tests), and of including Inhibin A, the most
recent routine addition to serum marker combinations.
Investigation of sources of heterogeneity
We investigated whether a uniform screening test is suitable for
all women, or whether different screening methods are more ap-
plicable to different groups, deﬁned by advanced maternal age,
ethnic groups and aspects of the pregnancy and medical history
such as multiple pregnancy, diabetes and family history of Down’s
syndrome. We also considered whether there existed evidence of
overestimation of test accuracy in studies evaluating risk equations
in the derivation sample rather than in a separate validation sam-
ple.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies in which all women from a given popula-
tion had one or more index test(s) compared to a reference stan-
dard. Both consecutive series and diagnostic case-control study
designs were included. Randomised trials where individuals were
randomised to different screening strategies and all veriﬁed us-
ing a reference standard were also eligible for inclusion. Studies
in which test strategies were compared head-to-head either in the
same women, or between randomised groups were identiﬁed for
inclusion in separate comparisons of test strategies. Studies were
excluded if they included less than ﬁve Down’s syndrome cases, or
> 20% of participants were not followed up.
Participants
Pregnant women at between 14 and less than 24 weeks gestation
conﬁrmed by ultrasound, who had not undergone previous testing
for Down’s syndrome in their pregnancy were eligible. Studies
were included if the pregnant women were unselected, or if they
represented groups with increased risk of Down’s syndrome, or
difﬁculty with conventional screening tests including maternal age
greater than 35 years old, multiple pregnancy, diabetes mellitus
and family history of Down’s syndrome.
Index tests
The following index tests were examined; Alpha feto-protein
(AFP), unconjugated oestriol (uE3), total human chorionic go-
nadotropin (total hCG), free ß human chorionic gonadotropin
(free β hCG), free alpha human chorionic gonadotropin (free α
hCG), Inhibin A, SP2, CA125, Troponin, pregnancy-associated
plasma protein A (PAPP-A), placental growth factor (PGF) and
proform of eosinophil major basic protein (ProMBP), and com-
binations of these markers combined with maternal age. Combi-
nations without maternal age were not analysed, however, infor-
mation on such test combinations is provided.
We looked at comparisons of tests in isolation and in various com-
binations. These included single (one marker), double (two mark-
ers), triple (three markers), quadruple (four markers) and quin-
tuple (ﬁve markers) test strategies, all maternal age-adjusted. We
also looked at combinations that included Inhibin A as this has
been the most recently routinely introduced marker.
Where tests were used in comparison, we looked at the perfor-
mance of test comparisons according to predicted probabilities
computed using risk equations and dichotomised into high risk
and low risk.
Target conditions
Down’s syndrome in the fetus due to trisomy, translocation or
mosaicism.
Reference standards
Weconsidered several reference standards, involving chromosomal
veriﬁcation and postnatal macroscopic inspection.
Amniocentesis and CVS are invasive chromosomal veriﬁcation
tests undertaken during pregnancy. They are highly accurate, but
the process carries a 1% miscarriage rate, and therefore they are
only used in pregnancies considered to be at high risk of Down’s
syndrome, or on the mother’s request. All other types of testing
(postnatal examination, postnatal karyotyping, birth registers and
Down’s syndrome registers) are based on information available at
the end of pregnancy. The greatest concern is not their accuracy,
but the loss of the pregnancy tomiscarriage between the serum test
and the reference standard. Miscarriage with cytogenetic testing
of the fetus is included in the reference standard where available.
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We anticipated that older studies, and studies undertaken in older
women are more likely to have used invasive chromosomal veriﬁ-
cation tests in all women.
Studies undertaken in younger women and more recent studies
were likely to use differential veriﬁcation as they often only used
prenatal karyotypic testing on fetuses considered screen positive/
high risk according to the screening test; the reference standard for
most unaffected infants being observing a phenotypically normal
baby. Although the accuracy of this combined reference standard
is considered high, it is methodologically a weaker approach as
pregnancies that miscarry between the index test and birth are
likely to be lost from the analysis, and miscarriage is more likely
to occur in Down’s than normal pregnancies. We investigated the
impact of the likely missing false negative results in sensitivity
analyses.
Search methods for identification of studies
Electronic searches
We applied a sensitive search strategy to search the following
databases. We used one generic search strategy to identify studies
for all reviews in this series.
Databases searched included;
• MEDLINE via OVID (1980 to 18 May 2007)
• EMBASE via Dialog Datastar (1980 to 18 May 2007)
• BIOSIS via EDINA (1985 to 18 May 2007)
• CINAHL via OVID (1982 to 18 May 2007)
• The Database of Abstracts of Reviews of Effectiveness (The
Cochrane Library 2007, Issue 1)
• MEDION
• The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (www.ifcc.org/)
• The National Research Register (May 2007)
• Health Services Research Projects in Progress database (
HSRPROJ)
The search strategy combined three sets of search terms (see:
Appendix 1). The ﬁrst set was made up of named tests, general
terms used for screening/diagnostic tests and statistical terms.Note
that the statistical terms were used to increase sensitivity and were
not used as a methodological ﬁlter to increase speciﬁcity. The sec-
ond set was made up of terms that encompass Down’s syndrome
and the third set made up of terms to limit the testing to pregnant
women. All termswithin each set were combinedwith the Boolean
operator OR and then the three sets were combined using AND.
The terms used were a combination of subject headings and free
text terms. The search strategy was adapted to suit each database
searched.
We attempted to identify cumulative papers which reported data
from the same data set, and contacted authors to obtain clariﬁ-
cation of the overlap between data presented in these papers, in
order to prevent data from the same women being analysed more
than once.
Searching other resources
In addition, we examined references cited in studies identiﬁed as
being potentially relevant, and those cited by previous reviews.
We contacted authors of studies where further information was
required. We did not apply a diagnostic test ﬁlter, and we did not
apply language restrictions to the search.
We carried out forward citation searching of relevant items, us-
ing the search strategy in ISI citation indices, Google scholar and
PubMed ‘related articles’.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts (where avail-
able) of all studies identiﬁed by the search strategy. Full text ver-
sions of studies identiﬁed as being potentially relevant were ob-
tained and independently assessed by two review authors for in-
clusion, using a study eligibility screening pro forma according
to the pre-speciﬁed inclusion criteria. Any disagreement between
the two authors was settled by consensus, or where necessary, by
a third party.
Data extraction and management
A data extraction formwas developed and piloted using a subset of
20 identiﬁed studies.Two review authors independently extracted
data, andwhere disagreement or uncertainty existed, a third author
validated the information extracted.
Data on eachmarker were extracted as binary test positive/test neg-
ative results for Down’s and non-Down’s pregnancies, with a high-
risk result - as deﬁned by each individual study - being regarded as
test positive (suggestive or diagnostic of Down’s syndrome), and
a low risk result being regarded as test negative (suggestive of ab-
sence of Down’s Syndrome).Where results were reported at several
thresholds data were extracted at each.
Note was made of those in special groups which posed either
increased risk of Down’s syndrome or difﬁculty with conventional
screening tests including maternal age greater than 35 years old,
multiple pregnancy, diabetesmellitus and family history ofDown’s
syndrome.
Assessment of methodological quality
Weused amodiﬁed version of theQUADAS tool (Whiting 2003),
a quality assessment tool for use in systematic reviews of diagnostic
accuracy studies, to assess the methodological quality of included
studies. We anticipated that a key methodological issue would be
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the potential for differential veriﬁcation bias arising from the use
of different invasive tests (amniocentesis versus CVS). Further bias
was likely to arise from follow-up for the reference standard ac-
cording to index test results. Finally, we expected to ﬁnd bias as
a result of miscarriage, where karyotyping was not performed, as
this could potentially inﬂuence the false negative and true negative
rates. We chose to code this issue as originating from differential
veriﬁcation in the QUADAS tool: we are aware that it could also
be coded under delay in obtaining the reference standard, and re-
porting of withdrawals. We omitted the QUADAS item assess-
ing quality according to length of time between index and refer-
ence tests, as Down’s syndrome is either present or absent rather
than a condition that evolves and resolves, and disregarding the
differential reference standard issue any length of delay is accept-
able. Two review authors assessed each included study separately.
Any disagreement between the two review authors was settled by
consensus, or where necessary, by a third party. Each item in the
QUADAS tool was be marked as ‘yes’, ‘no’ or ‘unclear’, and scores
are presented graphically and in tables. We have not used a sum-
mary quality score.
QUADAS criteria included the following ten questions:
1. Was the spectrum of women representative of the women
who will receive the test in practice? (Criteria met if the sample
was selected from a wide range of childbearing ages, or selected
from a speciﬁed ‘high-risk’ group such as over 35s, family history
of Down’s Syndrome, multiple pregnancy or diabetes mellitus,
provided all affected and unaffected fetuses were included that
could be tested at the time point when the screening test would
be applied; criteria not met if the sample taken from a select or
unrepresentative group of women (i.e. private practice), was an
atypical screening population or recruited at a later time point
when selection could be affected by selective fetal loss.)
2. Is the reference standard likely to correctly classify the target
condition? (amniocentesis, CVS, postnatal karyotyping,
miscarriage with cytogenetic testing of the fetus, a phenotypically
normal baby or birth registers are all regarded as meeting this
criteria.)
3. Did the whole sample or a random selection of the sample
receive veriﬁcation using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless
of the index test result?
5. Was the reference standard independent of the index test
result (i.e. the index test did not form part of the reference
standard)?
6. Were the index test results interpreted without knowledge
of the results of the reference standard?
7. Were the reference standard results interpreted without
knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight,
ethnic origin, gestational age) available when test results were
interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?
Statistical analysis and data synthesis
Results of all tests evaluated across all common risk thresholds for
screen positive result were initially examined using forest plots and
plotting study results in ROC space. Test strategies were selected
for further investigation if they were evaluated in four or more
studies or, if there were three or fewer studies, but the individual
study results indicated performance likely to be superior to a sen-
sitivity of 70% and speciﬁcity of 90%.
Estimation of average sensitivity and specificity
The analysis for each test strategy was undertaken ﬁrst restricting
to studies which reported a common threshold to estimate aver-
age sensitivity and speciﬁcity rates for each test at each threshold.
Although data on all thresholds were extracted, we present only
key common thresholds close to risks of 1:384, 1:250 and the 5%
FPR, unless other thresholds were more commonly reported. The
thresholds chosen are those most commonly quoted in studies.
There have been recent moves to reduced the FPR from 5% to
3% in some countries, in order to reduce the number of invasive
tests performed, but this has only recently become commonplace
in the literature. Where combinations of tests were used in a risk
score, we extracted the result for the test combination using the
risk score and not the individual components that made up the
test.
Meta-analyses were undertaken using hierarchical summary ROC
curve methods which included estimation of random effects in
accuracy and threshold parameters when there were four or more
studies. Otherwise, average sensitivity and speciﬁcity values were
computed using separate univariate random-effects meta-analysis,
averaging the logit sensitivity and logit speciﬁcity as inadequate
data would be available to estimate all parameters in the HSROC
model. It is common in this ﬁeld for studies to report sensitivity
for a ﬁxed speciﬁcity (usually a 5% false positive rate). This re-
moves the requirement to use a bivariate meta-analytical method
for analysis at this threshold as all speciﬁcity rates are the same,
hence logit sensitivity values were also pooled using a univariate
random-effects method. All analyses were undertaken using the
METADAS macro for SAS.
Comparisons between tests
Comparisons between tests were ﬁrst made utilising all available
studies, selecting one threshold from each study to estimate a sum-
mary ROC curve without restricting to a common threshold. The
threshold was chosen for each study according to the following
order of preference a) the risk threshold closest to 1 in 250; b) a
multiples of the median (MoM) or presence/absence threshold; c)
the performance closest to a 5% false positive rate (FPR) or 95th
percentile. The 5% false positive rate was chosen as a cut-off point
7Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
as this is the cut-off most commonly reported in the literature.
The analysis including data from all studies ﬁtted a single HSROC
model including the 12 selected test strategies, including two in-
dicator terms for each test to allow for differences in accuracy and
threshold. As there was limited evidence of differing SROC curve
shapes between tests, a single SROC shape parameter was included
in the model such that the ﬁtted SROC curves did not cross. An
estimate of the sensitivity of each test for a 5% false positive rate
was derived from the summary ROC curve, and associated conﬁ-
dence interval obtained using the delta method.
Direct comparisons between tests were based on results of very
few studies, and were analysed using a ﬁxed-effect HSROCmodel
with symmetrical underlying SROC curves as there were inade-
quate data to estimate between study heterogeneity in accuracy
and threshold or asymmetric shape. A separate model was used
to make each pair wise comparison. Comparisons between tests
were assessed by the signiﬁcance of differences in accuracy, and ex-
pressed as relative diagnostic odds ratios reported with 95% con-
ﬁdence intervals. As studies rarely reported data cross-classiﬁed
by both tests for Down’s and normal pregnancies, the analytical
method did not take full account of the pairing of test results, but
the restriction to direct head-to-head comparisons should have re-
moved the potential confounding of test comparisons with other
features of the studies. The strength of evidence for differences
in performance of test strategies relied on evidence from both the
direct and indirect comparisons.
Investigations of heterogeneity
Investigations of heterogeneity were only undertaken when there
were 10 or more studies available for a test. Subgroup analyses
were undertaken by adding covariates for differences in accuracy
and threshold to the HSROC meta-analytical model.
Sensitivity analyses
In many of the included studies, mothers with pregnancies iden-
tiﬁed as high risk for Down’s syndrome by the serum testing were
offered immediate deﬁnitive testing by amniocentesis, whereas,
the remainder were assessed for Down’s syndrome by inspection
at birth. Such delayed and differential veriﬁcation will introduce
bias most likely through there being greater loss to miscarriage in
the Down’s syndrome pregnancies that were not detected by the
serum testing (the false negative diagnoses). Testing and detection
of miscarriages is impractical in many situations, and no clear data
are available on the magnitude of these miscarriage rates.
To account for the possible bias introduced by such a mechanism,
we undertook sensitivity analyses where we inﬂated the false neg-
ative count in studies where delayed veriﬁcation in test negatives
occurred (Mol 1999). This was undertaken for two analyses - the
main comparison of the 12 key test combinations, and the in-
vestigation of the impact of maternal age on test sensitivity. For
both analyses, we increased the percentage of false negatives in
each study incrementally from 10% to 50%, the ﬁnal value rep-
resenting a scenario where a third more Down’s pregnancies than
normal pregnancies were likely to miscarry, thought to be higher
than the likely value.
R E S U L T S
Results of the search
The search for the whole suite of reviews identiﬁed a total of
13,403 papers, once the results from each bibliographic database
were combined and duplicates were removed. After screening out
obviously inappropriate papers based on their title and abstract 904
papers remained and copies were obtained for formal assessment
of eligibility. From these a total of 239 studies were deemed eligible
and included in the suite of reviews. A total of 59 studies (reported
in 72 publications) were included in this review of second trimester
serum screening, involving 341,261 pregnancies including 1994
Down’s syndrome pregnancies.
A total of 54 different test strategies combinations were evaluated
in the 59 studies. These tests are produced from combinations of
12 different tests, with and without maternal age; AFP, uE3, total
hCG, freeβ hCG, freeα hCG, InhibinA, SP2, CA125, Troponin,
PAPP-A, PGF and ProMBP. Strategies evaluated included three
quintuple tests, ﬁve quadruple, 12 triple, 14 doubles and nine
single tests in combination with age; the remaining 11 assessed
single tests without age. Forty-two of the 59 studies only evaluated
the performance of a single second trimester serum test or test
strategy, seven compared two, a further seven compared between
three and six, one compared 11 (Bartels 1994a), one compared 20
(Wald 2003a) and one compared 21 (Forest 1995).
The following combinations evaluated included four ormore stud-
ies:
Quadruple tests
• Total hCG, uE3, AFP, Inhibin A and maternal age (ﬁve
studies, 38,342 women, including 232 Down’s syndrome
pregnancies)
Triple tests
• Total hCG, uE3, AFP and maternal age (24 studies, 89,047
women, including 648 Down’s syndrome pregnancies)
• Free β hCG, AFP and uE3 and maternal age (seven studies,
10,541 women, including 249 Down’s syndrome pregnancies)
Double Tests
• Total hCG, AFP and maternal age (15 studies, 133,783
women, including 473 Down’s syndrome pregnancies)
• Free β hCG, AFP and maternal age (12 studies, 45,597
women including 341 Down’s syndrome pregnancies)
Single tests
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• Total hCG and maternal age (four studies, 57,768 women
including 280 Down’s syndrome)
• AFP and maternal age (four studies, 13,764 women,
including 173 Down’s syndrome pregnancies)
• Free β hCG and maternal age (four studies, 14,985
women, including 192 Down’s syndrome pregnancies)
Of the remaining test combinations, seven were evaluated in two
studies and the remaining 28 in single studies only.
Methodological quality of included studies
Methodological quality of the studies was judged to be high in
most categories (Figure 1). Due to the nature of testing for Down’s
syndrome screening and the potential side effects of invasive test-
ing, differential veriﬁcation is almost universal in the general
screening population, as most women whose screening test result
is deﬁned as low risk will have their screening test veriﬁed at birth,
rather than by invasive diagnosis in the antenatal period. Addi-
tionally, it was not always possible to ascertain from the included
studies whether or not the results of index tests and reference stan-
dards were blinded. It would be difﬁcult to blind clinicians per-
forming invasive diagnostic tests (reference standards) to the index
test result, unless all women received the same reference standard,
which would not be appropriate in most scenarios. However, any
biases secondary to a lack of clinician blinding are likely to be
minimal.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Most studies reported 100% follow-up, however, there will in-
evitably be losses to follow-up due to women moving out of area,
for example. Studies usually accounted for these and it is unlikely
to have introduced signiﬁcant bias. There was deﬁnitely under
ascertainment of miscarriage, and very few papers accounted for
miscarriage or performed tissue karyotyping in pregnancies result-
ing in miscarriage. Some studies attempted to adjust for predicted
miscarriage rate and the incidence of Down’s syndrome in this spe-
ciﬁc population, but most did not. We have not attempted to ad-
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just for expected miscarriage rate in this review but have explored
the impact in a sensitivity analysis. This issue has the potential to
have more inﬂuence with ﬁrst trimester testing due to a higher
miscarriage rate per se in this trimester.
Some studies which provided estimates of risk using multivariable
equations used the same data set to evaluate performance of the
risk equation as was used to derive the equation. This is often
thought to lead to over-estimationof test performance. The impact
of inclusion of these studies was investigated in subgroup analyses,
reported below.
Findings
1) Total hCG, AFP, uE3, Inhibin A and maternal age (Quadru-
ple test) (Figure 2)
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Figure 2. Studies evaluating combination of maternal age, Total hCG, AFP, uE3 and Inhibin showing
summary ROC curve
Results for this quadruple test were derived from ﬁve studies
(Debieve 2000; Malone 2005; Palomaki 2006; Wald 2003a;
Wenstrom 1999), and included 38,342 women in whom 150
pregnancies were known to be affected by Down’s syndrome.
Thirty-ﬁve thousand two hundred and thirty-six (95% of total
pregnancies) including 87 Down’s cases (58%) originated from
the FASTER study (Malone 2005). Wald 2003a and Wenstrom
1999 contributed over 1,000 pregnancies each to the data. Stud-
ies presented data for cut-points of 5% FPR (Wald 2003a),
1;150 (Debieve 2000; Palomaki 2006; Wenstrom 1999), 1:250
(Debieve 2000; Palomaki 2006), 1:270 (Wenstrom 1999) and 1:
300 (Malone 2005). At a cut-point of 5% FPR, Wald estimated a
sensitivity of 80.5% (95% conﬁdence interval (CI) 70.3 to 88.4).
At a cut-point of 1:250 (two studies), the sensitivity is estimated
at 73.9% (95% CI 60.0 to 84.2) and the speciﬁcity is 94.8% (CI
92.8 to 96.2); at a cut-point of 1:300 Malone estimated the sen-
sitivity at 85.0% (CI 75.8 to 91.8) and the speciﬁcity at 91.5%
(CI 91.2 to 91.8).
2) Free βhCG, AFP, uE3 and maternal age (Triple test) (Figure
3)
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Figure 3. Studies evaluating combination of maternal age, Free ßhCG, AFP and uE3 showing summary
ROC curve
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Results for this triple test were derived from seven studies (Ciofﬁ
2000; Extermann1998; Forest 1995;Knight 1998; Sancken 2003;
Wald 2003a; Wenstrom 1997a ), including 10,541 women, in
whom 249 pregnancies were known to be affected by Down’s syn-
drome. Over half of the women were derived from Knight’s study.
Studies presented data from cut-points of 5% FPR (Knight 1998;
Sancken 2003; Wald 2003a), 1:250 (Ciofﬁ 2000; Wald 2003a),
1:384 (Forest 1995) and 1:380 (Extermann 1998). At a cut-point
of 5% FPR, the estimated sensitivity was 65.1% (95% CI 46.4
to 80.1). At the cut-point of 1:250, the estimated sensitivity was
81.5% (95%CI 72.5 to 88.1) for an estimated speciﬁcity of 97.9%
(95% CI 87.7 to 99.7).
3) Total hCG, AFP, uE3 and maternal age (Triple test)(Figure
4)
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Figure 4. Studies evaluating combination of maternal age, Total hCG, AFP and uE3 showing summary ROC
curve
Results for this triple test were derived from 24 studies (Bahado-
Singh 1999a; Bahado-Singh 2000; Bartels 1994a (divided into
Bartels 1994a and Bartels 1994b); David 1996; Debieve 2000;
Extermann 1998; Forest 1995; Haddow 1994; Heyl 1990;
Huderer-Duric 2000; Kishida 2000; Knight 1998;Mancini 1991;
Perona 1997; Piggott 1994;Rosen 2002; Sancken 2003; Suzumori
1997; Verloes 1995; Wald 2003a Ward 1999; Wenstrom 1997a;
Wenstrom 1999) and included 89,047 women, in whom 648 were
known to be affected byDown’s syndrome.Of the 24 studies, there
are four with a sample size of over 5,000 (David 1996; Haddow
1994; Knight 1998; Piggott 1994), two over 10,000 (Verloes
1995; Ward 1999) and one over 20,000 (Perona 1997). Seven
studies evaluated sensitivity at 5% FPR (Bahado-Singh 1999a;
Bahado-Singh 2000; Bartels 1994a; Haddow 1994; Knight 1998;
Sancken 2003; Wald 2003a), ﬁve evaluated a cut-point of 1:250
(David 1996; Debieve 2000; Mancini 1991; Piggott 1994; Ward
1999). At a cut-point of 5% FPR, the estimated sensitivity was
53.5% (95% CI 43.0 to 63.7). At the cut-point of 1:250, the
estimated sensitivity was 76.9% (95% CI 52.7 to 90.9) for an
estimated speciﬁcity of 93.6% (95% CI 87.7 to 96.8).
4) Total hCG, AFP and maternal age (Double test) (Figure 5)
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Figure 5. Studies evaluating combination of maternal age, Total hCG and AFP showing summary ROC
curve
Results for this double test were derived from 15 studies (Audibert
2001a; Bartels 1994a; Beekhuis 1993; Benattar 1999; Crossley
1994; David 1996; Debieve 2000; Forest 1995; Jou 2000; Knight
1998; Lam 2002; Lemay 1995; Milunsky 1993; Roberts 2000;
Wald 2003a) and included 133,783 women, in whom 473 preg-
nancies were known to be affected by Down’s syndrome. Of the
15 studies, four presented data on with sample sizes of greater
than 15,000 (Jou 2000; Lam 2002; Lemay 1995; Roberts 2000)
and one with greater than 30,000 (Crossley 1994). Four studies
gave data for a cut-point of 5% FPR (Bartels 1994a; Knight 1998;
Lam 2002; Wald 2003a), six studies gave data for a cut-point of
1:250 (Audibert 2001a; Beekhuis 1993; Benattar 1999; David
1996; Debieve 2000; Roberts 2000). At a cut-point of 5% FPR,
the estimated sensitivity was 61.7% (95% CI 53.5 to 69.2), and at
the cut-point of 1:250, the estimated sensitivity was 69.9% (95%
CI 60.3 to 78.1) for a speciﬁcity of 95.3% (95% CI 94.3 to 96.2)
.
5) Free β hCG, AFP and maternal age (Double test) (Figure 6)
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Figure 6. Studies evaluating combination of maternal age, Free ßhCG and AFP showing summary ROC
curve
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Results for this double test were derived from 12 studies (
Anandakumar 1999; Brajenovic 1998; Chao 1999; Extermann
1998; Forest 1995; Hsu 1997a; Kadir 1999; Knight 1998;
Milunsky 1993; Rozenberg 2002;Wald 2003a;Wenstrom 1997a)
including 45,597 women, of which 341 were affected by Down’s
syndrome. Of the 12 studies, four presented data on more than
5,000 women (Chao 1999; Hsu 1997a; Knight 1998; Rozenberg
2002). Five studies gave data for a 5% FPR (Anandakumar 1999;
Hsu 1997a;Knight 1998;Rozenberg 2002;Wald 2003a) and three
for a cut-point of 1:250 (Brajenovic 1998; Kadir 1999; Rozenberg
2002). At a cut-point of 5% FPR, the estimated sensitivity was
61.7% (95% CI 52.7 to 69.9), and at the cut-point of 1:250,
the estimated sensitivity was 75.5% (95% CI 60.1 to 86.4) for a
speciﬁcity of 91.6% (95% CI 90.5 to 92.6) .
6) Total hCG and maternal age (Single test) (Figure 7)
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Figure 7. Studies evaluating combination of maternal age and Total hCG showing summary ROC curve
Results for this single test were derived from four studies (Forest
1995; Knight 1998;Muller 1996a;Wald 2003a) including 57,668
pregnancies of which 280 were known to be affected by Down’s
syndrome. Of the four studies, two presented data on more than
5,000 women (Knight 1998; Muller 1996a). Three studies gave
data for a 5% FPR cut-point (Knight 1998; Muller 1996a; Wald
2003a). At this cut-point the sensitivity was estimated at 56.1%
(95% CI 41.0 to 70.2). The cut-point for Forest 1995 was 1:384
and is included on the ﬁgure.
7) Free β hCG and maternal age (Single test) (Figure 8)
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Figure 8. Studies evaluating combination of maternal age and Free ßhCG showing summary ROC curve
Results for this single test were derived from four studies (Forest
1995; Hsu 1997a; Knight 1998; Wald 2003a) including 14,985
pregnancies, of which 192 were known to be affected by Down’s
syndrome. Of the four studies, Hsu 1997a was the largest, pre-
senting data on more than 9,000 pregnancies.Three studies gave
data for a cut-point of 5% FPR (Hsu 1997a; Knight 1998; Wald
2003a). At this cut-point the sensitivity was estimated at 52.6%
(95% CI 37.4 to 67.4). The cut-point for Forest 1995 was 1:384
and is included on the ﬁgure.
8) AFP and maternal age (Single test) (Figure 9)
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Figure 9. Studies evaluating combination of maternal age and AFP showing summary ROC curve
Results for this single test were derived from four studies of 13,764
pregnancies including 173 Down’s syndrome pregnancies (Forest
1995; Hsu 1997a; Rose 1994; Wald 2003a). Of the four stud-
ies, (Hsu 1997a) was the largest presenting data on 8,265 (48%)
of pregnancies including 47 Down’s syndrome pregnancies. Stud-
ies presented data for cut-points of 5% FPR (Hsu 1997a; Wald
2003a), 1:270 (Rose 1994) and 1:384 (Forest 1995). Two studies
gave data for a cut-off of 5% FPR estimating a sensitivity of 41.9%
(95% CI 33.7 to 50.5) .
9) Other test combinations (Figure 10)
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Figure 10. Studies of four promising test combinations evaluated in in only one or two studies
Of the 36 test combinations evaluated in one or two studies,
only four test combinations demonstrated estimated sensitivities
of more than 70% and estimated speciﬁcities of more than 90%.
• A quintuple test of total hCG, AFP, uE3, Inhibin A,
PAPP-A and maternal age evaluated in a single study (Wald
2003a) estimated a sensitivity of 82.9% (CI 73.0 to 90.3%) at a
cut-point of 5% FPR.
• A quintuple test of free βhCG, AFP, uE3, Inhibin A,
PAPP-A and maternal age evaluated in a single study (Wald
2003a) estimated a sensitivity of 84.1% (CI 74.4 to 91.3%) at a
cut-point of 5% FPR.
• A quadruple test of free βhCG, uE3, AFP, Inhibin A and
maternal age evaluated in Wald 2003a estimated a sensitivity of
84.1% (CI 74.4 to 91.3) and speciﬁcity of 94.3% (CI 92.6 to
95.6) at a cut-point of 1 in 250. However, a second evaluation in
Wenstrom 1999 estimated much lower values.
• A triple test of total hCG, Inhibin A, AFP and maternal
age evaluated in a single study (Debieve 2000) estimated a
sensitivity of 88.9% (CI 65.3 to 98.6) for a speciﬁcity of 93.5%
(CI 89.1 to 96.5) at a cut-point of 1:250.
10) Individual markers
There were data available on 10 individual markers, not combined
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with maternal age, the results of which are presented in the forest
plots available in the full review report. There was substantial
heterogeneity noted in the sensitivities of Inhibin A and SP2 in
these studies.
Comparative analysis of the eleven selected test strategies
Formal statistical comparison of the 12 test strategies listed above
was made using HSROC meta-analytical models, ﬁrstly to quan-
tify the difference in test performance (expressed with 95% con-
ﬁdence intervals), and secondly to assess the strength of evidence
of real differences in performance between the strategies. Com-
parative analysis was undertaken by comparing summary ROC
curves estimated by ﬁrst making pair wise comparisons pooling
studies which made compared tests in the same mothers, and then
by pooling all available studies for the 12 test strategies listed
above. Estimates of the differences in accuracy obtained from the
HSROCmodels are expressed as relativeDORs which are not easy
to interpret. To provide more accessible estimates of performance,
we have also computed the detection rate (sensitivity) for a ﬁxed
false positive rate (speciﬁcity), a metric which is commonly used
in Down’s syndrome screening to describe performance.We chose
to estimate detection rates at a 5% FPR, in common with much
of the literature.
Figure 11 shows point estimates of detection rates for a 5% FPR
based on all available data for all 12 test combinations described
above, and the conﬁdence intervals at a ﬁxed 5% FPR. For exam-
ple, the plot shows that for the triple test with a marker combi-
nation of free βhCG, AFP, uE3 and maternal age the estimated
detection rate at a 5% FPR is 70.1% (95% CI 61.8 to 77.3) based
on data from seven studies with 249 affected cases and 10,541
total participants.The test combinations in the Figure are ordered
according to decreasing detection rates. The three single test strate-
gies (AFP with maternal age; total hCGwith maternal age and free
βhCG with maternal age) have the worst performance, whereas,
the ﬁve triple, quadruple and quintuple strategies containing in-
hibin have the highest performance. In between lie the standard
triple tests (total hCG, AFP, uE3 and maternal age; free-βhCG,
AFP, uE3 and maternal age) and double tests (total hCG, AFP
and maternal age; free βhCG, AFP and maternal age). However,
it is noted that the conﬁdence intervals on these estimates are wide
(particularly for the inhibin-based combinations) and overlap for
the ﬁrst six strategies, suggesting that any of the differences ob-
served may be explicable by chance.
Figure 11. Detection rates (% sensitivity) at a false positive rate of 5% for the 12 selected test combinations
(estimates from summary ROC curves)
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Table 1 shows pair wise direct comparisons (head-to-head) where
studies were available. Such comparisons are regarded as provid-
ing the strongest evidence as they are unconfounded. The table
shows the ratios of DOR with 95% CI and P values for each test
combination, the number of studies (K) for which data were avail-
able. The table shows that the diagnostic accuracy of the single test
combinations (AFP andmaternal age, total hCG andmaternal age
and free βhCG and maternal age) tends to be signiﬁcantly worse
(P < 0.05) than the double, triple, quadruple and quintuple tests
where data are available. The double test comprised of total hCG,
AFP and maternal age also appears to have signiﬁcantly worse (P
< 0.05) test accuracy than quadruple and quintuple test combina-
tions containing inhibin. Otherwise, there was no strong evidence
of signiﬁcant differences in test accuracy between triple, quadruple
and quintuple tests containing inhibin and the standard double
(total hCG, AFP and maternal age; free βhCG, AFP and maternal
age) and triple tests (total hCG, AFP, uE3 and maternal age; free-
βhCG, AFP, uE3 and maternal age). However, most comparisons
in this table are based on only single studies and are unlikely to be
powered to detect differences in detection rates.
Table 2 shows the same comparisons made using all available data
(as used to create Figure 10). Results are in agreement with the di-
rect comparisons, and in addition, showed some statistically signif-
icance differences (P <0.05) suggesting that quintuple andquadru-
ple tests containing inhibin and total hCG outperform standard
double tests (total hCG, AFP and maternal age; free βhCG, AFP
and maternal age) and one standard triple test (total hCG, AFP,
uE3 and maternal age). However, these comparisons are poten-
tially confounded by differences between the studies.
Investigations of heterogeneity and subgroup analysis
Three test combinations included 10 or more studies allowing
investigation of sources of heterogeneity (two double tests (free
β hCG, AFP and maternal age; total hCG, AFP and maternal
age) and one triple test (total hCG, AFP, uE3, and maternal age)).
Adequate data were only available to consider the impact of two
potential sources: advanced maternal age and the use of the same
data set for deriving and evaluating the risk equation (derivation
versus validation). The results of these two comparisons for each
of the three tests are presented in Table 3.
There is a signiﬁcant difference in sensitivity for women over the
age of 35 years for two test combinations. The double test com-
prised of free β hCG, AFP and maternal age showed a signiﬁ-
cant decrease in sensitivity in women over 35 years of age when
compared to a standard screening population (51.7% sensitivity
versus 66.4% for a ﬁxed 5% FPR (P = 0.03)) with a larger decrease
being observed for the triple test comprised of total hCG, AFP,
uE3 and maternal age (48.4% versus 68.6% for a ﬁxed 5% FPR
(P < 0.0001)). A non-signiﬁcant difference of the samemagnitude
was noted for the double test comprised of total hCG, AFP and
maternal age.
No signiﬁcant differences or consistent effects were noted when
comparing evaluations undertaken in the same data sets used for
derivation of the risk equation rather than separate validation data
sets for any of the three test combinations.
Results of sensitivity analysis investigating the impact of pos-
sible pregnancy loss through delayed veriﬁcation of test nega-
tives
Figure 11 shows the results of the sensitivity analysis comparing
test combinations when the number of false negatives are inﬂated
by 50% in studies with delayed veriﬁcation of test negatives. The
estimate of the sensitivity decreases for all test combinations, with
a small degree of variability in magnitude, but not large enough to
cause any reordering of the performance of the tests. Thus it ap-
pears that the ranking of tests is not affected by delayed veriﬁcation
of test negatives in studies which ascertained Down’s syndrome at
birth in those at low risk.
Table 4 reports results of the investigation of the effect of maternal
age, with similar inﬂations of false negatives from 10% to 50% in
studies with delayed veriﬁcation of test negatives. Delayed veriﬁ-
cation was not common in studies undertaken entirely in women
aged 35 or over as they tended to be offered amniocentesis on
the basis of the increased risk associated with advanced maternal
age alone, and the corrections to the false negatives made very lit-
tle difference to the estimates of sensitivity. However, in younger
mothers the correction reduced sensitivity, and consequently re-
duced the apparent relationship between maternal age and test
performance, observed through the ratio of diagnostic odds ratios
approaching one. But even with an increase of 50% in the false
negatives cells, the difference in sensitivity between age-groups for
the triple test comprised of total hCG, AFP, uE3, andmaternal age
remained statistically signiﬁcant, although its magnitude nearly
halved from 20% to 12%. The effect seen for the double test com-
prised of free β hCG, AFP and maternal age combination lost
its borderline signiﬁcance with even the smallest increase in false
negatives.
Summary of results
Summary of results 1. Performance of the 12 most evaluated and best performing second trimester serum strategies
Studies Women (cases) Sensitivity* (95%CI) at
a 5% FPR
Tests shown inferior in
direct comparisons (P <
0.05)
Tests shown inferior in
indirect comparisons (P
< 0.05)
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Summaryof results 1. Performanceof the12most evaluated andbest performing second trimester serumstrategies (Continued)
Quintu-
ple Tests (with ma-
ternal age)
free ßhCG
AFP uE3 Inhibin A
and PAPP-A
1 1,092 (82) 84 (71,92) All single tests; total-
hCG+AFP
All single tests; All dou-
ble tests; total-
hCG+AFP+uE3
Quadru-
ple Tests (with ma-
ternal age)
total hCG AFP uE3
Inhibin PAPP-A
1 1,092 (82) 83 (69, 92) All single tests; total-
hCG+AFP
All single tests; All dou-
ble tests; total-
hCG+AFP+uE3
total hCG AFP uE3
Inhibin
5 38,342 (232) 77 (68, 84) All single tests; total-
hCG+AFP
All single tests; All dou-
ble tests; total-
hCG+AFP+uE3
free ßhCGAFP uE3
Inhibin
2 2,348 (95) 74 (58, 85) All single tests; total-
hCG+AFP
All single tests
Triple Tests (with
maternal age)
total hCG AFP In-
hibin
2 564 (51) 82 (63, 92) All single tests; total-
hCG+AFP+uE3
total hCG AFP uE3 24 89,047 (648) 61 (55, 66) All single tests total-hCG, AFP
free ßhCGAFP uE3 7 10,541 (249) 70 (62, 77) All single tests All single tests
Double Tests (with
maternal age)
total hCG AFP 15 133,783 (473) 66 (60, 72) All single tests All single tests
free ßhCG AFP 12 45,597 (341) 65 (58, 72) total-hCG; AFP All single tests
Single Tests (with
maternal age)
free ßhCG 4 14,985 (192) 52 (42, 62) AFP
total hCG 4 57,768 (280) 50 (40, 59)
AFP 4 13,764 (173) 41 (31, 53)
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* these ﬁgures for sensitivity can be interpreted as the number of women out of every hundred carrying a Down’s syndrome fetus who
would be detected when the test is used at a cut off point corresponding to a 5% false positive rate. They have been calculated based
on all available data using a single meta-analytical model.
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Summary of results 2. Performance of the remaining 31 second trimester serum strategies (all involving maternal age)
Studies Women (cases) Sensitivity* (95% CI) Speciﬁcity* (95% CI) Threshold
Single tests (with
maternal age)
uE3 2 1603 (93) 65 (33, 87) 92 (81, 97) mixed
Free ßhCG to AFP
ratio
1 8265 (47) 62 (46,75) 95 5% FPR
Inhibin 2 1117 (87) 59 (48, 68) 95 5% FPR
PAPP-A 2 1117 (87) 38 (20, 59) 95 5% FPR
ProMBP 1 256 (105) 49 (39,59) 95 (90,98) 1:250 risk
Free ßhCG 1 511 (11) 73 (39,94) 89 (86,91) 1:384 risk
Double tests (with
maternal age)
Total hCG and free
ßhCG
1 511 (11) 55 (23,83) 82 (79,86) 1:384 risk
Total hCG and uE3 2 881 (61) 63 (27,89) 92 (79,97) mixed
Total hCG and SP1 1 370 (50) 44 (30,59) 95 5% FPR
Total hCG and free
ßhCG
1 511 (11) 82 (48,98) 86 (83,89) 1:384 risk
Free ßhCG and uE3 1 511 (11) 73 (39,94) 83 (79,86) 1:384 risk
Free ßhCG and free
αhCG
1 511 (11) 73 (39, 94) 87 (84,90) 1:384 risk
AFP and uE3 2 881 (61) 49 (14,85) 92 (81,97) mixed
uE3 and free ßhCG 1 511 (11) 82 (48,98) 85 (82,88) 1:384 risk
uE3 and SP1 1 370 (50) 36 (23,51) 95 5% FPR
AFP and SP1 1 370 (50) 34 (21,49) 95 5% FPR
AFP and Hypergly-
cosylated hCG
1 328 (50) 54 (39,68) 95 5% FPR
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Summary of results 2. Performance of the remaining 31 second trimester serum strategies (all involving maternal age)
(Continued)
AFP and free ßhCG 1 511 (11) 82 (48,98) 85 (82,88) 1:384 risk
Triple tests (with
maternal age)
Total hCG, free
ßhCG and AFP
1 344 (31) 87 (70,96) 82 (77,86) 1:266 risk
Total hCG, uE3 and
SP1
1 370 (50) 44 (30,59) 95 5% FPR
Total hCG, AFP
and SP1
1 370 (50) 50 (36,64) 95 5% FPR
Total hCG, AFP
and CA125
1 328 (22) 82 (60,95) 84 (80,88) 1:190 risk
Free ßhCG, AFP
and Inhibin A
1 1256 (13) 62 (32,86) 80 (78,82) 1:190 risk
Free ßhCG, AFP
and ProMBP
1 334 (107) 60 (50,69) 95 5% FPR
Free ßhCG, AFP
and uE3
1 511 (11) 100 (72,100) 78 (74,81) 1:384 risk
AFP, uE3 and In-
hibin A
1 346 (33) 88 (72,97) 79 (74,83) 1:233 risk
AFP, uE3 and SP1 1 370 (50) 38 (25,53) 95 5% FPR
Quadru-
ple tests (with ma-
ternal age)
Total hCG,
free ßhCG,AFP and
uE3
1 511 (11) 64 (31,89) 85 (82,88) 1:384 risk
Total hCG, AFP,
uE3 and free αhCG
1 511 (11) 91 (59,100) 85 (81,88) 1:384 risk
Total hCG, AFP,
uE3 and SP1
1 370 (50) 50 (36, 64) 95 5% FPR
Quintu-
ple tests (with ma-
ternal age)
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Summary of results 2. Performance of the remaining 31 second trimester serum strategies (all involving maternal age)
(Continued)
Total hCG, free
ßhCG, AFP, uE3,
and free αhCG
1 511 (1) 91 (59,100) 86 (82,89) 1:384 risk
* Sensitivity and speciﬁcity values obtained by separate pooling of sensitivities and speciﬁcities where there are two studies.
D I S C U S S I O N
Summary of main results
The systematic review found a large number of studies evaluating
second trimester Down’s syndrome serum screening tests, includ-
ing studies evaluating the commonly used double and triple tests.
Fewer studies were available to evaluate the performance of test
strategies involving inhibin, which have been more recently de-
veloped, and few studies provided unconfounded comparisons of
test strategies by applying and comparing several strategies using
the same serum sample, the majority of studies only evaluating
a single test combination. A summary of results for the 12 most
common and best performing strategies is given in this Summary
of results 1, briefer details for the remaining 31 strategies are given
in Summary of results 2.
Six key ﬁndings were noted.
1. Double and triple tests signiﬁcantly outperform the use of
single tests. Single tests (total hCG with maternal age, free
βhCG with maternal age and AFP with maternal age) detect
only between four and ﬁve out of every 10 Down’s syndrome
pregnancies when used at a threshold corresponding to a 5%
false positive rate. Standard triple tests (total hCG, AFP, uE3 and
maternal age; free βhCG, AFP, uE3 and maternal age) and
double tests (total hCG, AFP and maternal age; free βhCG, AFP
and maternal age) detect between six and seven out of every 10
Down’s syndrome pregnancies at the same threshold.
2. Whilst the four quintuple, quadruple and triple test
combinations including inhibin show the highest detection rates
(total hCG, AFP, uE3, inhibin and PAPP-A with maternal age;
total hCG, AFP, uE3 and inhibin with maternal age; free βhCG,
AFP, uE3 and Inhibin A with maternal age; and total hCG, AFP
and inhibin with maternal age), they were not shown to be
statistically superior to double and triple tests that do not include
inhibin in the direct comparisons. Whilst some signiﬁcant
differences between these categories of tests were noted in the
indirect comparisons, the potential for confounding (particularly
related to study year) is of concern. Estimates suggest that
inhibin-based combinations may detect between seven and eight
out of every 10 Down’s syndrome pregnancies at a 5% false
positive rate. With the exception of the quadruple test comprised
of free βhCG, uE3, AFP and inhibin with maternal age (n =
2348), the number of pregnancies studied for these
combinations was markedly smaller than for test combinations
excluding inhibin. It is therefore difﬁcult to make strong
recommendations on the use or exclusion of inhibin as a marker
in combined tests, as we cannot conclude there are no differences
as there is limited power to detect them.
3. The evidence that quintuple tests are signiﬁcantly better at
detecting Down’s syndrome than quadruple tests or triple tests is
not strong, and similarly quadruple tests are not shown to be
signiﬁcantly better than triple tests. Whilst the trend suggests
that the more markers used in a test, the higher the diagnostic
accuracy, the amount of evidence, particularly available for direct
comparisons, is insufﬁcient to make strong recommendations.
4. There was no obvious beneﬁt in using free βhCG over total
hCG. Six studies made direct comparisons between the two
alternative triple tests with no obvious difference in test accuracy
(ratio of DOR 1.0; 95%CI (0.7 to 1.6); P = 0.93); four studies
made direct comparisons between the two alternative double
tests also with no obvious difference (ratio of DOR 1.0; 95%CI
(0.6 to 1.6); P = 0.91).
5. The sensitivity of tests in women over the age of 35 years is
markedly reduced. Evidence was available for three tests at a ﬁxed
5% FPR showing reductions in detection rates of between 10%
and 20%. Part of this effect may be explained by studies in
younger mothers missing false negative cases lost through
increased miscarriage in Down’s pregnancies, but this does not
fully explain the full effect. We are unable to draw any
conclusions as to why this may be the case. There was no obvious
difference in algorithms used to calculate risk, the marker assays
used, nor was there any obvious difference in the dates of the
studies involved. There may be differences in placental function
in women over 35 years of age that explains the differences in
performance of markers, however, this is conjecture.
Strengths and weaknesses of the review
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This review is the ﬁrst comprehensive review of second trimester
serum screening. It has examined papers from around the world,
covering a wide cross section of women in varying populations.
We have contacted authors to verify data where necessary to give
as complete a picture as possible while trying to avoid replication
of data.
There were a number of factors which have made meta-analysis
of the data difﬁcult, which we have tried to adapt for in order to
allow for comparability of data presented in different studies.
1. There are many different cut-points used to deﬁne
pregnancies as high or low risk for Down’s syndrome. This
means that direct comparison is more difﬁcult than if all studies
used the same cut-point to dichotomise their populations.
2. There are many different risk equations and software
applications in use for combination of multiple markers, which
were often not described in the papers. This means that risks
may be calculated by different formulae, and they may not be
directly comparable for this reason. It is possible that this is
responsible for confounding results.
3. Different laboratories and clinics run different assays and
use different machines and methods. This may inﬂuence raw
results and subsequent risk calculations. Many laboratories have
a quality assessment/audit trail, however, this may not necessarily
be standard across the board, for example, how many assays are
run, how often medians are calculated and adjusted for a given
population and how quickly samples are tested from initially
being taken.
4. Few papers make direct comparisons between tests, making
it difﬁcult to detect if there is a real difference between tests (i.e.
how different tests perform in the same population). There are
differences in populations, with assay medians being affected, for
example, by race. It is not certain whether it is appropriate to
make comparisons between populations which are inherently
different.
5. We were unable to perform many of the subgroup analyses
that we had originally intended to, as the data simply were not
available. The vast majority of papers looking at pregnancies
conceived by IVF, affected by diabetes, multiple gestation or a
family history of Down’s syndrome involved unaffected
pregnancies only
The major methodological concern in the primary studies relates
to the loss of pregnancies from the studies through miscarriage
that occurs between serological testing and obtaining the reference
standard. In studies where the patient sample were women attend-
ing for an amniocentesis no delay would occur between the serum
test and reference standard, and data on all pregnancies would be
available. In more standard clinical populations invasive testing is
only offered to high-risk pregnancies - in these studies to women
with high-risk serum test results. The remainder are assessed at
birth for phenotypic features of Down’s syndrome, but some will
be lost during follow-up due to miscarriage, and are suspected to
be omitted from study reports. Even though these problems oc-
cur, the sensitivity analysis we have undertaken indicate that the
ranking of the included tests is not affected by such differential
and delayed veriﬁcation and drop-out.
Applicability of findings to clinical practice and
policy
Potentially, where planning screening policy or a clinical screening
programme, clinicians and policy makers need to make decisions
about a ﬁnite number of tests or type of tests that can be offered.
These policies are often driven by both the needs of a speciﬁc pop-
ulation and by ﬁnancial resources. Economic analysis was consid-
ered to be outside of the scope of this review. Many of the tests
examined as part of this review are already commercially available
and in use in the clinical setting. The studies were carried out on
populations of typical pregnant women and therefore, the results
should be considered comparable with most pregnant populations
encountered in every day clinical practice.
We were also unable to extract information about harms of test-
ing, information about miscarriage rates and uptake of deﬁnitive
testing as the data were not available the majority of the time.
Whilst it is unlikely that major differences between the tests eval-
uated here exist in terms of direct harms of testing, as they are all
based on a single blood sample, differences in accuracy may lead
to differences in the use of deﬁnitive testing and its consequent
adverse outcomes.
In some countries with a deﬁned screening policy (i.e. the UK),
second trimester screening no longer plays a major role. In others
however, there may only be a limited range of tests or markers
available - often second trimester markers. The results of this re-
view should be interpreted and applied in the context of test avail-
ability and local restrictions, populations or policies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence for tests involving inhibin as a marker suggests a
superiority that is not found to be statistically signiﬁcant, and
based on small populations of women. We would not recommend
that these tests should be introduced into wider clinical practice
without careful consideration of cost.
The review has shown that tests involving two or three markers
in combination with maternal age are signiﬁcantly better than
those involving one marker. We would therefore recommend that
one marker tests are not used for Down’s syndrome screening.
The choice of multiple markers will depend on the availability of
certain assays in local laboratories. There was no test combination
shown to be superior to others therefore, we cannot recommend
a speciﬁc test combination.
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The performance of tests at earlier gestationswill be the subject of a
separate Cochrane review and the alternative ﬁrst trimester, cross-
trimester, ultrasound and combinations of serum and ultrasound
should also be considered when making policy decisions.
Implications for research
Further evaluation of inhibin-based test combinations are required
to determine whether their apparent advantages are not chance
ﬁndings. Further study of the attenuated performance of test com-
binations in women over 35 is required, as this age group has the
highest incidence of Down’s syndrome and has the greatest re-
quirement for tests with high detection rates.
Future studies should ensure that adequate sample sizes are re-
cruited, and take opportunities to make comparisons of test per-
formance testing several alternative test combinations on the same
serum samples. Such direct comparison removes issues of con-
founding when making test comparisons, and allows a clear focus
on testing the incremental beneﬁt of increasingly complex and
expensive testing strategies. The reporting of studies of test ac-
curacy can be improved and more closely adhere to the STARD
reporting standards. Three key aspects of this are 1) formally test-
ing the statistical signiﬁcance of differences in test performance in
direct comparisons and estimating incremental changes in detec-
tion rates (together with conﬁdence intervals), 2) clearly reporting
the number of mothers studied and their results, and 3) reporting
the numbers of women who are lost to follow-up. Many authors
reported results of extrapolating ﬁndings to age-standardised na-
tional cohorts to demonstrate the performance of the test, and
failed to report the actual numbers studied and evaluated.
For the purposes of meta-analysis and to allow for comparisons
to be made between different tests and combinations, we would
recommend the publication of consensus standard algorithms for
estimating risk, and reporting of test performance at a standard set
of thresholds. This would be difﬁcult to achieve and implement,
but an attempt at consensus should be made.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anandakumar 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing based on age
Participants 1208 participants
Singapore - single centre
1989-1991
Pregnant women over 35 years of age
Singleton pregnancies
Karyotyping performed at same time as serum sampling
12-22 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
7 affected cases
Reference standard - Amniocentesis
Index and comparator tests Maternal age
Second trimester serum AFP - Amerlite AFP assay
Second trimester serum ß hCG - Amerlite HCG-60 assay
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
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Anandakumar 1999 (Continued)
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Unclear No information given
Withdrawals explained?
All tests
Yes No withdrawals
Audibert 2001a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Routine screening
Participants 3790 participants
France - single centre
May 1994-December 1997
Pregnant women
Singleton pregnancies
CRL between 38 and 84 mm
Under 38 years of age
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
10 affected cases
Reference standards;
Amniocentesis
CVS
Postnatal karyotype
Miscarriage with cytogenetic testing
Neonatal examination
Index and comparator tests Maternal age
Second trimester serum hCG
Second trimester serum AFP
(Nuchal Translucency - see 1st trimester US review)
Amerlite, Orthoclinical diagnostics machine
Prenata software
Follow-up Delivery and postnatal paediatric examination
35 lost to follow-up and excluded from analysis
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Audibert 2001a (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Typical pregnant population with excep-
tion that women over 38 years of age ex-
cluded
Acceptable reference standard?
All tests
Yes Amniocentesis
CVS
Postnatal karyotype
Miscarriage with cytogenetic testing
Neonatal examination
Partial veriﬁcation avoided?
All tests
Yes All pregnancies veriﬁed by acceptable ref-
erence standard
Differential veriﬁcation avoided?
All tests
No Different reference standards used within
same population
Incorporation avoided?
All tests
Yes Index and reference tests separate
Reference standard results blinded?
All tests
Yes Results of index tests known prior to refer-
ence standard being performed
Index test results blinded?
All tests
Yes Results of index test unknown to operator
providing reference standard
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Bahado-Singh 1999a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 926 participants
USA
November 1995 - March 1999
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Bahado-Singh 1999a (Continued)
Pregnant women
Singleton pregnancies
Serum screening performed
15-24 weeks gestation
Euploid/Down’s karyotype only
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
21 affected cases
Reference standard - Amniocentesis
Index and comparator tests Maternal age
2nd trimester urinary ß core fragment
2nd trimester serum AFP
2nd trimester serum uE3
2nd trimester serum ß hCG
Spot specimens of urine - 2 step sandwich assay B120 monoclonal antibody
Serum not described
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Typical pregnant population
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Performed after index test
Index test results blinded?
All tests
Unclear No information given
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Bahado-Singh 1999a (Continued)
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Bahado-Singh 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 2371 participants
USA
January 1992 - November 1997
Pregnant women
Singleton pregnancies
14-24 weeks gestation
Euploid/Down’s karyotype only
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
46 affected cases
Reference standard - amniocentesis
Index and comparator tests Maternal age
2nd trimester serum AFP
2nd trimester serum uE3
2nd trimester serum ß hCG
Not described
Follow-up 100% karyotype
Notes Serum data analysed only
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Typical pregnant population
Acceptable reference standard?
All tests
Yes Amniocentesis
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Bahado-Singh 2000 (Continued)
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Reference standard performed after index
test performed
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Bartels 1990
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 325 participants
Germany and USA
Dates not speciﬁed
Known normal outcome or known aneuploidy
14-24/40 gestation
Study design Retrospective multi-centre case-control study
Target condition and reference standard(s) Down’s syndrome
43 affected cases
Reference standard not speciﬁed, but known karyotype
Index and comparator tests 2nd trimester hCG
2nd trimester SP-1
Tandem E hCG immunoenzymetric assay
Enzygnost SP1 assay
Follow-up 100% methods not speciﬁed
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Bartels 1990 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Unclear Implied karyotype - known outcome
Partial veriﬁcation avoided?
All tests
Yes All outcomes known
Differential veriﬁcation avoided?
All tests
Unclear No information given regarding method of
karyotype
Incorporation avoided?
All tests
Yes Reference and index test separate
Reference standard results blinded?
All tests
Yes Known prior to index test
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Bartels 1994a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk women referred for invasive testing
Participants 370 participants
Germany
14-21 weeks gestation
Study design Prospective consecutive series study
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Bartels 1994a (Continued)
Target condition and reference standard(s) Down’s syndrome
50 affected cases
Reference standard - Amniocentesis
Index and comparator tests Second trimester hCG, SP-1, uE3 and AFP with or without age
Amerlex M 2nd trimester kit for AFP, hCG and uE3
Enzygnost SP-1 for SP-1
Follow-up 100% Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk women referred for invasive test-
ing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Bartels 1994b
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk women referred for invasive testing
Participants 655 participants
Germany
14-21 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
10 affected cases
Reference standard - Amniocentesis
Index and comparator tests Second trimester hCG, SP-1, uE3 and AFP with or without age
Amerlex M 2nd trimester kit for AFP, hCG and uE3
Enzygnost SP-1 for SP-1
Follow-up 100% Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk women referred for invasive test-
ing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
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Bartels 1994b (Continued)
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Beekhuis 1993
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 2282 participants
Netherlands multi-centre
October 1st 1990-December 1st 1991
Pregnant women
Singleton pregnancies
15-20 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
6 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests Maternal age
Second trimester serum hCG
Second trimester serum AFP
EIA
Alpha software
Follow-up 100% karyotype
Notes Dutch language paper
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
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Beekhuis 1993 (Continued)
Differential veriﬁcation avoided?
All tests
No Reference standard differs according to in-
dex test result
Incorporation avoided?
All tests
Yes Index and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Benattar 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 1649 participants
France
January to December 1995
Pregnant women
Singleton pregnancies
Less than 13 weeks gestation at enrolment
15-18 weeks at time of second trimester serum screening
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
5 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests Maternal age
Second trimester serum AFP
Second trimester serum free ß hCG
Second trimester serum hCG
No test characteristics speciﬁed
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Benattar 1999 (Continued)
Follow-up Birth
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differs depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes 12 lost to follow-up
Brajenovic 1998
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 3188 participants
Croatia
January 1996-December 1996
Pregnant women
Same ethnic group (not speciﬁed)
14-22 weeks
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Brajenovic 1998 (Continued)
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
9 affected cases
Reference standard;
Amniocentesis
Maternity record, cytogenetics records and patient questionnaires
Index and comparator tests Second trimester maternal serum AFP
Second trimester maternal serum free ß hCG
EMIA coated tubes
ELISA assay - CIS Bio international
Follow-up 3 months after delivery
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Maternity record, cytogenetics records and
patient questionnaires
Partial veriﬁcation avoided?
All tests
Yes All pregnancies veriﬁed by reference stan-
dard
Differential veriﬁcation avoided?
All tests
No High risk received amniocentesis, low risk
received postnatal veriﬁcation as stated
above
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to references standard
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
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Brajenovic 1998 (Continued)
Withdrawals explained?
All tests
Yes None
Brizzi 1989a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 1472 participants
Italy
Dates not speciﬁed
Pregnant women
Biparietal diameter 32-48 mm
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
27 affected cases
Amniocentesis
Index and comparator tests Second trimester Maternal serum AFP
No technical information provided
Follow-up 100% Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
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Brizzi 1989a (Continued)
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Chao 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 10098 participants
Taiwan
1st July 1994- 30th April 1996
Pregnant women
15-23 weeks gestation
Singleton pregnancies
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
15 affected cases
Reference standards;
Amniocentesis
Postnatal examination
Telephone follow-up of high-risk cases
Index and comparator tests Maternal age
Second trimester maternal serum AFP
Second trimester maternal serum free ß hCG
Beta hCG - solid phase 2 site immunoradiometric assay
AFP - enzyme immunoassay kit
Follow-up 85% Known outcome
Notes 85% follow up only
Table of Methodological Quality
Item Authors’ judgement Description
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Chao 1999 (Continued)
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Telephone follow-up of high-risk cases
Partial veriﬁcation avoided?
All tests
No Outcome known in 85% only, but all high-
risk women offered invasive testing
Differential veriﬁcation avoided?
All tests
No Reference standard differed depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
No 15% loss to follow-up not explained
Christiansen 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 261 participants
Denmark
Dates not speciﬁed
Pregnant women
Known outcome
5-20 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
105 affected cases
Karyotyping
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Christiansen 1999 (Continued)
Index and comparator tests 1st trimester serum ProMBP
2nd trimester serum ProMBP
2 site immunoradiometric assay samples reduced and alkylated and added to microtitre
wells coated with monoclonal antibody J13 6B6
Follow-up 100% Birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Typical screening population
Acceptable reference standard?
All tests
Yes Karyotyping
Partial veriﬁcation avoided?
All tests
Yes All women received karyotyping
Differential veriﬁcation avoided?
All tests
No All women received karyotyping
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrsopective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Christiansen 2004
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 334 participants
Denmark
Dates not speciﬁed
Pregnant women
Singletons
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
107 affected cases
Reference standard;
Amniocentesis
CVS
Postnatal karyotype
Index and comparator tests Maternal age
Second trimester maternal serum ß hCG
Second trimester maternal serum AFP
Second trimester maternal serum Pro MBP
Pro-MBP - 2 site immunoradiometric assay (IRMA)
Free ß hCG and AFP - AutoDELFIA analytical system
Follow-up Retrospective - Known outcome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
CVS
Postnatal karyotype
Partial veriﬁcation avoided?
All tests
Yes All outcomes known
Differential veriﬁcation avoided?
All tests
No Different reference standards used within
population
Incorporation avoided?
All tests
Yes Index test and reference standards separate
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Christiansen 2004 (Continued)
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Outcome unknown to assessor
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Ciofﬁ 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 717 participants
Italy
Dates not speciﬁed
Pregnant women
15-21 weeks gestation
No family history of NTD/DM/DS
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
17 affected cases
Reference standard;
Amniocentesis
Postnatal follow-up
Index and comparator tests Maternal age
Second trimester maternal serum uE3
Second trimester maternal serum AFP
Second trimester maternal serum ß hCG
Isotopic methods
uE3 - Bio rad clin division
AFP and ß hCG - Immunosystems company
Follow-up Postnatal period
Notes
Table of Methodological Quality
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Ciofﬁ 2000 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal follow-up
Partial veriﬁcation avoided?
All tests
Yes All outcomes veriﬁed
Differential veriﬁcation avoided?
All tests
No High risk only received amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Crossley 1994
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 30084 participants
UK
1991-1992
Singleton pregnancies
15-20 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
37 affected cases
Reference standards;
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Crossley 1994 (Continued)
Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Postnatal examination
Index and comparator tests Maternal age
2nd Trimester serum AFP
2nd Trimester serum total hCG
Serone MAIA clone
Follow-up 100% birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All veriﬁed by reference standard
Differential veriﬁcation avoided?
All tests
No Different women received different refer-
ence standard depending on index test re-
sult
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
No No explanation given
Withdrawals explained?
All tests
Yes None
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David 1996
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 9500 participants
Israel
June 1991-October 1993
Pregnant women
SIngleton pregnancies
Study design Case-control study - controls collected prospectively and cases collected retrospectively
Target condition and reference standard(s) Down’s syndrome
47 affected cases
Amniocentesis
Postnatal examination
Index and comparator tests Maternal age
Second trimester maternal serum uE3
Second trimester maternal serum AFP
Second trimester maternal serum hCG
DELFIA Wallac - AFP and hCG
Amerlex radioimmunoassay - uE3
Follow-up Not stated
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
No Reference standard differed
Differential veriﬁcation avoided?
All tests
No Different women received different refer-
ence standard depending on index test re-
sult
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
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David 1996 (Continued)
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Debieve 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 218 participants
Belgium
Dates not speciﬁed
Pregnant women
15-20 weeks gestation
Singletons
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
18 affected pregnancies
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests Maternal age
Second trimester maternal serum hCG
Second trimester maternal serum uE3
Second trimester maternal serum AFP
Second trimester maternal serum Inhibin A
Amerlex M 2T RIA kits for hCG, uE3 and AFP
2 monoclonal antibody solid-phase sandwich microtitre plate ELISA Serotec Oxford for
Inhibin A
Follow-up Known outcome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Debieve 2000 (Continued)
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All outcomes veriﬁed
Differential veriﬁcation avoided?
All tests
No Only high-risk women had amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Extermann 1998
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 2539 participants
Switzerland
June 1992 - June 1993
Pregnant women
Known outcome
15-18 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
23 affected cases
Reference standard - amniocentesis and implied postnatal veriﬁcation but not speciﬁed
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Extermann 1998 (Continued)
Index and comparator tests Maternal age
Second trimester maternal serum hCG
Second trimester maternal serum free ß hCG
Second trimester maternal serum AFP
Second trimester maternal serum uE3
AFP - IMX (Abbott)/ES 600
Total hCG - IMX/Status (Baxter)
uE3 and free ß hCG - RIA using Kodak Amerlex M Estriol kit
Follow-up Birth
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis and implied postnatal veri-
ﬁcation
Partial veriﬁcation avoided?
All tests
Yes All outcomes ascertained
Differential veriﬁcation avoided?
All tests
No Reference standard offered depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Forest 1995
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 511 participants
Canada
June 1989 - October 1993
Singleton pregnancies
9-18 weeks gestation
Study design Prospective consecutive series
Target condition and reference standard(s) Down’s syndrome
11 affected cases
Reference standard;
Amniocentesis
Review of maternal and neonatal records
Index and comparator tests AFP
uE3
Total hCG
Free alpha hCG
Free ß hCG
AFP/hCG - Enzymum test enzyme immunoassay (Boehringer Mannheim, Canada)
uE3 - Radioimmunometric assay (DSL Canada)
Free alpha and ß hCG - Radioimmunometric assay (Bioclone Austria pty Ltd)
Follow-up 100% Birth/Karyotype
Notes 3 different models used for risk calculation (Wald, Spencer and Ryall)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Maternity and neonatal records
Partial veriﬁcation avoided?
All tests
Yes All outcomes veriﬁed
Differential veriﬁcation avoided?
All tests
No Reference standard differs depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
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Forest 1995 (Continued)
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Greenberg 1991
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 3282 participants
USA
1985 onwards
Pregnant women
Singleton pregnancy
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
51 affected cases
Reference standards;
Amniocentesis
Postnatal karyotype
Postnatal examination
Index and comparator tests Second trimester serum AFP alone
Clinical assays, Cambridge, Massachusetts
Follow-up 100% - known outcome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting -screening programme
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Greenberg 1991 (Continued)
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received veriﬁcation by refer-
ence standard
Differential veriﬁcation avoided?
All tests
No Different reference standards used depend-
ing on index test result
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Known outcome - retrospective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Haddow 1994
Clinical features and settings Request for Down’s syndrome screening in pregnancy
HIgh-risk referral for invasive testing
Participants 5336 participants
USA
December 1990 - October 1992
Pregnant women
35 years of age and over
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
54 affected cases
Reference standard - Amniocentesis
Index and comparator tests 2nd trimester serum AFP
2nd trimester serum uE3
2nd trimester serum hCG
Maternal age at delivery
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Haddow 1994 (Continued)
AFP - In house assay
uE3 - Amerlex M radioimmunoassay kit speciﬁc for uE3
hCG - Amerlex M extended range hCG radioimmunoassay kit
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Index test result not known to operator
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Haddow 1998
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 308 participants
USA
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Haddow 1998 (Continued)
December 1990 - October 1992
Pregnant women
35 years of age and over
Study design Retrospective case-control study
Target condition and reference standard(s) Down’ syndrome
52 affected cases
Reference standard - amniocentesis
Index and comparator tests 2nd trimester serum Inhibin A
InhibinAmeasured induplicate using a solid phase sandwich enzyme linked immunosor-
bent assay (ELISA)
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Index test result unknown to operator
Index test results blinded?
All tests
Yes Carried out prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
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Haddow 1998 (Continued)
Withdrawals explained?
All tests
Yes None
Heyl 1990
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 101 participants
USA
January 1986 - January 1990
Greater than 35 years
Singleton pregnancies
Study design Retrospective single-centre case-control study
Target condition and reference standard(s) Down’s syndrome
16 affected cases
Reference standard - Amniocentesis
Index and comparator tests 2nd trimester AFP
2nd trimester hCG
2nd trimester uE3
Maternal Age
1 in 365 risk
AFP - Abbott enzyme immunoassay
hCG - IMx system total ß hCG assay
uE3 - Amerlex M unconjugated oestriol
Follow-up 100%
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
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Heyl 1990 (Continued)
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Index test result not known at time of ref-
erence standard being carried out
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Hsu 1997a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 8265 participants
Taiwan
1992-1996
Pregnant women
Singletons
14-23 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
47 affected cases
Reference standards;
Amniocentesis
Neonatal examination
Index and comparator tests Maternal age
Second trimester serum free ß hCG
Second trimester serum AFP
Abbott EIA-AFP
Free ß hCG ELSA kit
Cuckle 1987 formula
Follow-up Birth/Karyotype
Notes
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Hsu 1997a (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Neonatal examination
Partial veriﬁcation avoided?
All tests
Yes All women had reference standard per-
formed
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Reference standard performed prior to in-
dex test
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Huderer-Duric 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
HIgh-risk referral for invasive testing
Participants 2833 participants
Croatia
1996-1998
Pregnant women
Singletons
15-22 weeks gestation
Study design Prospective consecutive series study
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Huderer-Duric 2000 (Continued)
Target condition and reference standard(s) Down’s syndrome
12 affected cases
Amniocentesis
Index and comparator tests Maternal age
Second trimester maternal serum uE3
Second trimester maternal serum hCG
Second trimester maternal serum AFP
Amerlax M
Prenata software
Follow-up Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Operator not aware of index test result at
time of amniocentesis
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Jou 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 17742 participants
Taiwan
June 1994-July 1998
Pregnant women
14-22 weeks gestation
Singletons
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
16 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Postnatal karyotype
Index and comparator tests Maternal age
Second trimester maternal serum hCG
Second trimester maternal serum AFP
AFP - microparticle enzyme immunoassay kit
hCG - CMEIA AFP kit and MEIA ß hCG kit
RAM programme - body weight corrected MoM and maternal age
Follow-up Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Postnatal karyotype
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Refence standard differs depending on in-
dex test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
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Jou 2000 (Continued)
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Kadir 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 4427 participants
England
1/4/93 - 31/3/95
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
13 affected cases
Reference standards;
Amniocentesis
Postnatal examination
Index and comparator tests 2nd trimester AFP
2nd trimester free ß hCG
Maternal age
1 in 250 risk at EDD
AFP - immunoradiometric assay (omnia alpha FP)
Free ß hCG - speciﬁc solid phase 2 site immunoradiometric assay (ELISA fBhCG)
Follow-up 100% karyotype or postnatal examination
Notes 9.4% of study population older than 37 years
Table of Methodological Quality
Item Authors’ judgement Description
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Kadir 1999 (Continued)
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women had reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Index test performed prior to reference
standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Kishida 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme, but 63% of women over 35 yrs of age
Participants 1055 participants
Japan
May 1995-Feb 1998
Pregnant women
Singleton pregnancies
14-20 weeks
No major pregnancy complications
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
10 affected cases
Reference standards;
Amniocentesis
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Kishida 2000 (Continued)
Clinical neonatal examination
Index and comparator tests Maternal age
Second trimester maternal serum AFP
Second trimester maternal serum hCG
Second trimester maternal serum uE3
AFP - Abbott laboratories
hCG - Wallac
uE3 - Diagnostic products, LA
Follow-up 100% birth/karyotype
Notes 63% of women over 35 yrs of age
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Neonatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Index test results unknown to operator
Index test results blinded?
All tests
Yes Index test performed prior to reference
standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Knight 1998
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 5117 participants
USA
December 1990 - October 1992
Pregnant women
35 years of age and over
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
52 affected pregnancies
reference standard - Amniocentesis
Index and comparator tests Second trimester serum hCG
Second trimester serum free ß hCG
Second trimester serum AFP
Second trimester serum uE3
Maternal age
Free ß hCG and AFP - Wallac DELFIA hAFP/free ß hCG dual assay
hCG - hCG MAIA clone
uE3 - Amerlex M radioimmunoassay kit speciﬁc for uE3
Follow-up 100% Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Yes Results of index test unknown to operator
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Knight 1998 (Continued)
Index test results blinded?
All tests
Yes Index test performed prior to reference
standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Lam 2002
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 16237 participants
Taiwan
June 1994-July 1998
Pregnant women
15-20 weeks gestation for serum analysis
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
35 affected cases
Reference standards;
Amniocentesis
CVS
Neonatal examination
Index and comparator tests Maternal age
Second trimester maternal serum AFP
Second trimester maternal serum hCG
Test characteristics not described in paper
Follow-up Birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
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Lam 2002 (Continued)
Acceptable reference standard?
All tests
Yes Amniocentesis
CVS
Neonatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differs depending on
index test result
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
No Index test result known to operator
Index test results blinded?
All tests
Yes Index test performed prior to reference
standard
Relevant clinical information?
All tests
Unclear No clear information given
Uninterpretable results reported?
All tests
Yes Miscarriages etc excluded from analysis
Withdrawals explained?
All tests
Yes None
Lemay 1995
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 18600 participants
France
October 1989 to December 1993
Pregnant women
15-18 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
32 affected cases
Refernce standards;
Amniocentesis
Postnatal karyotype
Postnatal examination
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Lemay 1995 (Continued)
Index and comparator tests Second trimester serum total hCG
Second trimester serum total AFP
Maternal age
Arcus 1230 2 site immunoﬂuorimetric assay (DELFIA)
Follow-up 100% birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differs depending on
index test result
Incorporation avoided?
All tests
Yes Index test and reference standard separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Results not available to operator
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Malone 2005
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 35236 participants
USA - 15 centres
October 1999 - December 2002
Pregnant women
Maternal age >16 years
Singleton live fetus
Fetal CRL 36-79 mm (10+3 - 13+6/40 at recruitment)
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
87 affected cases
Reference standards;
Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Neonatal examination
Index and comparator tests Maternal age
Second trimester maternal serum AFP
Second trimester maternal serum total hCG
Second trimester maternal serum uE3
Second trimester maternal serum Inhibin A
Test characteristics not speciﬁed
Follow-up Birth/karyotype
Notes Cystic hygroma analysed separately
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Neonatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differs depending on
index test result
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Malone 2005 (Continued)
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Mancini 1991
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 731 participants
Italy
1989-1990
Pregnant women
15-18 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
9 affected cases
Reference standard - amniocentesis
Index and comparator tests 2nd trimester serum uE3
2nd trimester serum hCG
2nd trimester serum AFP
Maternal age
AFP - DELFIA hAFP kit
hCG - DELFIA hCG
uE3 - Unconjugated RIA
Follow-up 100% karyotype
Notes
Table of Methodological Quality
101Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mancini 1991 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
No All women had amniocentesis
Incorporation avoided?
All tests
Yes Index test and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Milunsky 1993
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 511 participants
USA
Dates not speciﬁed
Normal singleton pregnancy versus known Down’s pregnancy
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
31 affected cases
Reference standards;
Amniocentesis
Postnatal examination
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Milunsky 1993 (Continued)
Index and comparator tests Intact hCG
Free ß hCG
MSAFP
Maternal age
Cases that had not undergone more than 2 freeze thaw cycles
Free ß by commercial immunoradiometric assay (CIS UK Ltd)
Intact hCG by immunoradiometric solid phase assay (Serone MAIA clone)
Follow-up 100% Birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Yes Performed without knowledge of reference
standard
Relevant clinical information?
All tests
Yes Appropriate clinical information provided
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Muller 1996a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 51048 participants
France
1989-1993
15-17/40 gestation
Singleton pregnancies
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
135 affected cases
Reference standard;
Amniocentesis
Postnatal Karyotype
Postnatal examination
Index and comparator tests 2nd trimester maternal serum hCG
Greater than or equal to 1% risk of Down’s
hCG high values, SFRI, Bordeaux, France
Follow-up 100% by karyotype or postnatal examination
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting- screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal Karyotype
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
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Muller 1996a (Continued)
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Palomaki 2004
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 283 participants
USA 14 centres
1990-1992
Pregnant women
14-21 weeks gestation
SIngleton pregnancies
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
45 affected cases
Reference standard - amniocentesis
Index and comparator tests 2nd trimester serum Invasive trophoblast antigen
Maternal age
Automated immuno chemiluminometric assay
Follow-up 100% birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
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Palomaki 2004 (Continued)
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Yes Outcome unknown to operator
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Palomaki 2006
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 540 participants
USA single centre
Dec 1 1999-October 31 2003
Pregnant women
Known Down’s or normal pregnancy
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
32 affected cases
Reference standard - Outcome obtained from Ontario Multiple Marker screening
database
Index and comparator tests Second trimester maternal serum PAPP-A
Alpha logical medical systems software
Repeated measures method
Perkin Elmer assay
Follow-up Known outcome
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Palomaki 2006 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Genetic database
Karyotyping
Partial veriﬁcation avoided?
All tests
Yes All women had known outcome
Differential veriﬁcation avoided?
All tests
No Reference standard differed
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Pandian 2004
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme AND High-risk referral for invasive testing
Participants 100 participants
USA
Dates not speciﬁed
Pregnant women
Singleton pregnancies
Study design Retrospective case-control study
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Pandian 2004 (Continued)
Target condition and reference standard(s) Down’s syndrome
16 affected cases
Reference standard ;
Amniocentesis
Known pregnancy outcome
Index and comparator tests Second trimester maternal serum ITA
Second trimester maternal serum AFP
Second trimester maternal serum uE3
Second trimester maternal serum hCG
Second trimester maternal serum Inhibin A
ITA - Diagnostic System Laboratories
AFP/uE3/hCG/Inhibin A - Immulite 2000
Follow-up Birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
ANDHigh-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
’Known pregnancy outcome’
Partial veriﬁcation avoided?
All tests
Yes All had reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differed
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Performed prior to index test analysis
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
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Pandian 2004 (Continued)
Withdrawals explained?
All tests
Yes None
Perona 1997
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 20856 participants
Italy
October 1991-December 1995
Pregnant women
Singleton pregnancies
30-35 years of age
15-18 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
41 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests 2nd trimester serum uE3
2nd trimester serum hCG
2nd trimester serum AFP
Maternal age
ALPHA software package
AFP - DELFIA hAFP kit
hCG - DELFIA hCG
uE3 - Unconjugated RIA
Follow-up 100% birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
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Perona 1997 (Continued)
Partial veriﬁcation avoided?
All tests
Yes All women had reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Piggott 1994
Clinical features and settings Request for Down’s syndrome screening in pregnancy
CLinical setting - screening programme
Participants 6990 participants
UK
January 1991-December 1992
Pregnant women
Singleton pregnancies
15-22 weeks gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
11 affected cases
Reference standard;
Amniocentesis
Neonatal examination and birth registers
Index and comparator tests Maternal age
Second trimester maternal serum AFP
Second trimester maternal serum uE3
Second trimester maternal serum hCG
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Piggott 1994 (Continued)
AFP and hCG - Delﬁa kits
uE3 - Amerlex M
Alpha software
Follow-up Birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Neonatal examination and birth registers
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to references standard
Relevant clinical information?
All tests
Unclear No information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Qin 1997
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
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Qin 1997 (Continued)
Participants 352 participants
Denmark - single centre
Dates not speciﬁed
Pregnant women
Known Down’s or normal pregnancy
5-9 weeks (for USS) or 14-20 weeks for serum
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
116 affected pregnancies
Reference standard;
Amniocentesis
CVS
Postnatal karyotype
Postnatal examination
Index and comparator tests Second trimester maternal serum SP1
Non-competitive time resolved immuno ﬂuorometric assay using rabbit antibody against
SP1
Multicalc software package
Follow-up Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
CVS
Postnatal karyotype
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differs
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
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Qin 1997 (Continued)
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Roberts 2000
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 26080 participants
England
February 1992 - January 1997
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
41 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests 2nd trimester AFP
2nd trimester hCG
Maternal age
1 in 250 risk
Amerlex-M 2T kit, ortho clinical diagnostics
Follow-up 100% karyotype/postnatal examination
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
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Roberts 2000 (Continued)
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Rose 1994
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 3896 participants
USA
1974-1990
Pregnant women
Greater than 35 years of age
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
33 affected cases
Reference standard;
Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Index and comparator tests Maternal age
Second trimester maternal serum AFP
Test characteristics not described
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Rose 1994 (Continued)
Follow-up Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differed depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Rosen 2002
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 1006 participants
Belgium
January 1991-September 1992
Pregnant women
14-24 weeks by USS
115Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rosen 2002 (Continued)
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
13 affected cases
Reference standard - Amniocentesis
Index and comparator tests Maternal age
Second trimester maternal serum uE3
Second trimester maternal serum hCG
Second trimester maternal serum AFP
Dried blood samples on blotting paper card
Non radioactive immunologic step followed by colorimetric quantiﬁcation of a
horseradish pre oxidase
Follow-up Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Performed immediately after venepuncture
for index test
Index test results blinded?
All tests
Yes Reference standard results not known
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
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Rosen 2002 (Continued)
Withdrawals explained?
All tests
Yes None
Rozenberg 2002
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 8297 participants
France (multi-centre)
March 1994 - December 1997
18-37 years of age
Singleton pregnancy
No family history of Down’s syndrome
12-14 weeks gestation at time of scan and 14+1 to 17 weeks at time of serum sample
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
20 affected cases
Reference standards;
Amniocentesis
Postnatal examination
Index and comparator tests NT
Second trimester serum free ß hCG
Second trimester serum AFP
Secdond trimester serum Maternal age
NT - FMF methods
SERUM - ß hCG ELISA immunoradiometric assay
AFP ELISA immunoradiometric assay
Follow-up 100% Birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
117Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rozenberg 2002 (Continued)
Differential veriﬁcation avoided?
All tests
No Different references standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Sancken 2003
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 221 participants
Germany
Dates not speciﬁed
Pregnant women
15-22 weeks gestation
Known pregnancy outcome
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
33 affected cases
Reference standard;
Amniocentesis
Postnatal karyotype
Postnatal examination
Index and comparator tests Maternal Age
Total hCG
Free ß hCG
AFP
uE3
Second trimester serum samples
AFP and uE3 - Radioimmunoassay
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Sancken 2003 (Continued)
Free ß hCG - Immunoradiometric assay
Follow-up 100% birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Different reference standard depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes One outlier excluded from analysis
Su 2002
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 356 participants
Taiwan
January 1995 - November 1998
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Su 2002 (Continued)
Singleton pregnancies
14-21 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
36 affected cases
Reference standard;
Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Index and comparator tests Placental growth factor
95th percentile
Sandwich enzyme immunoassay technique (R and D systems, Minneapolis USA)
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal karyotype
Miscarriage with cytogenetic testing
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Refence standard differs
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
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Su 2002 (Continued)
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Suzumori 1997
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 1078 participants
15-18 weeks gestation
Japan
April 1994 - March 1996
Singleton pregnancy
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
14 affected cases
Reference standard - amniocentesis
Index and comparator tests Second trimester serum AFP
Second trimester serum hCG
Second trimester serum uE3
Maternal age
AFP - Abbott Ltd USA
hCG - Wallac Finland
uE3 - Diagnostic products corps, USA
Follow-up 100% Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women had amniocentesis
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Suzumori 1997 (Continued)
Differential veriﬁcation avoided?
All tests
Yes All women had amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Yes Outcome unknown to operator
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Talbot 2003
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 328 participants
UK
Dates not speciﬁed
Singleton pregnancies
2nd trimester
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
50 affected cases
Reference standards;
Amniocentesis
Postnatal examination
Index and comparator tests Second trimester serum hCG glycoform
Second trimester serum free ß hCG
Second trimester serum AFP
Maternal age
hCG Glycoforms - Lectin immunoassay
free ß hCG, AFP, total hCG - Kryptor analyser (TRACE)
Follow-up 100% Birth/Karyotype
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Talbot 2003 (Continued)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting- screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Poatnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differed according to
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Index test results not known to operator
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Van Lith 1992
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 90 participants
The Netherlands
Dates not speciﬁed
Pregnant women
14-18 weeks gestation
Study design Retrospective case-control study
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Van Lith 1992 (Continued)
Target condition and reference standard(s) Down’s syndrome
10 affected cases
Reference standard - Amniocentesis
Index and comparator tests 2nd trimester serum Inhibin A
2 site enzyme immunoassay speciﬁc for alpha peptide of human Inhibin AEASIA appa-
ratus
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Verloes 1995
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 10454 participants
Belgium
January 1991-September 1992
Pregnant women
14-24 weeks by USS
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
15 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests Maternal age
Second trimester maternal serum uE3
Second trimester maternal serum hCG
Second trimester maternal serum AFP
Dried blood samples on blotting paper card
Non radioactive immunologic step followed by colorimetric quantiﬁcation of a
horseradish pre oxidase
Follow-up Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Refence standard differed
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
125Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Verloes 1995 (Continued)
Index test results blinded?
All tests
Yes Analysed without knowledge of karyotype
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Wald 2003a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 1092 participants
UK and Austria (multi-centre trial)
September 1996 to April 2000
Pregnant women booking at 8-14 weeks gestation by LMP and conﬁrmed by USS
Viable pregnancy
Study design Prospective nested case-control study
Target condition and reference standard(s) Down’s syndrome
82 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests NT at 9-13 weeks
Serum AFP, hCG, uE3, PAPP-A, free ß hCG, Inhibin A - 1st and 2nd trimester
Urinary ß core fragment, total hCG, ITA and free ß hCG - 1st and 2nd trimester
NT - midsaggital section, optimal magniﬁcation of thickness of translucent space be-
tween inner skin surface and fascia covering cervical spine (white black interface (outer)
- black white interface (inner))
41 models of ultrasound machine
20 minutes allotted scanning time
SERUM - Each Down’s pregnancy matched with 5 controls
AFP, free ß hCG, total hCG, uE3 and PAPP-A measured with time resolved ﬂuoroim-
munoassay (AutoDELFIA)
Inhibin A - Sandwich enzyme linked immunosorbent assay (Oxford bio innovation)
URINE - ITA and ß core fragment (Quest diagnostics USA)
Total hCG and free ß hCG as per serum
Follow-up 96% Birth/Karyotype full outcome documentation obtained
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Wald 2003a (Continued)
Notes Performance of screening assessed at 17 weeks gestation
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differed depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
No Known to operator prior to performing ref-
erence standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Ward 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
Clinical setting - screening programme
Participants 13613 participants
UK - single centre
1992-1997
Singleton pregnancies
15-18 weeks gestation
Study design Prospective consecutive series study
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Ward 1999 (Continued)
Target condition and reference standard(s) Down’s syndrome
16 affected cases
Reference standard;
Amniocentesis
Postnatal examination
Index and comparator tests 2nd trimester serum AFP
2nd trimester serum uE3
2nd trimester serum hCG
Maternal age
AFP - Amerlite 2T
hCG and uE3 - Amerlex M2T
Follow-up 100% birth/karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Clinical setting - screening programme
Acceptable reference standard?
All tests
Yes Amniocentesis
Postnatal examination
Partial veriﬁcation avoided?
All tests
Yes All women received reference standard
Differential veriﬁcation avoided?
All tests
No Reference standard differs depending on
index test result
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Yes Performed prior to reference standard
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
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Ward 1999 (Continued)
Withdrawals explained?
All tests
Yes None
Watanabe 2002
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 25 participants
Japan
Dates not speciﬁed
Singleton pregnancies
15-17 weeks gestation
Study design Prospective case-control study
Target condition and reference standard(s) Down’s syndrome
5 affected cases
Refernce standard - Amniocentesis
Index and comparator tests Second trimester serum PAPP-A
Second trimester serumInhibin A
Maternal age
PAPP-A - Amerlex M PAPP-A IRMA kit
Inhibin A - serotec dimeric Inhibin A immunoassay kit
Follow-up 100% Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
No All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
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Watanabe 2002 (Continued)
Reference standard results blinded?
All tests
Yes Index test result unknown to operator
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Wenstrom 1997
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 349 participants
USA
1992-1996
Pregnant women
14-20 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
33 affected pregnancies
Reference standard - Amniocentesis
Index and comparator tests Second trimester serum Inhibin A
Second trimester serum AFP
Second trimester serum uE3
Second trimester serum hCG
Maternal age
Inhibin A - ELISA (Serotec, Oxford)
Other serum tests see Wenstrom 1997a
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Wenstrom 1997 (Continued)
Representative spectrum?
All tests
Yes HIgh-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Wenstrom 1997a
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 344 participants
USA
1992-1996
Pregnant women
14-20 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
31 affected cases
Reference standard - amniocentesis
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Wenstrom 1997a (Continued)
Index and comparator tests Second trimester serum AFP
Second trimester serum uE3
Second trimester serum hCG
Second trimester serum free ß hCG
Second trimester serum
Maternal age
AFP - Saroﬁ Pasteur
Intact hCG - Nichols institute
uE3 - Diagnostic systems laboratory
Free ß hCG - CIS - US Bedford, solid phase 2 site sandwich immunoradiometric assay
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
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Wenstrom 1997b
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 328 participants
USA
1993-1995
Pregnant women
14-20 weeks gestation
Study design Retrospective case-control study
Target condition and reference standard(s) Down’s syndrome
22 affected cases
Reference standard - amniocentesis
Index and comparator tests Maternal age
Second trimester maternal serum CA125
Second trimester maternal serum AFP
Second trimester maternal serum hCG
CA125 - ELISA (Centocor)
AFP - Sanoﬁ pasteur
hCG - Nichols institute
Follow-up Birth/Karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Yes Retrospective study
133Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wenstrom 1997b (Continued)
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
Wenstrom 1999
Clinical features and settings Request for Down’s syndrome screening in pregnancy
High-risk referral for invasive testing
Participants 1256 participants
USA
August 1996 - August 1998
Pregnant women
14-20/40 gestation
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome
13 affected cases
Reference standard - amniocentesis
Index and comparator tests Second trimester serum AFP
Second trimester serum uE3
Second trimester serum total hCG
Second trimester serum free ß hCG
Second trimester serum Inhibin A
Maternal age
uE3 - Diagnostic systems laboratory, Texas
Inhibin A - Serotec, Oxford
AFP and total hCG - Chemoluminescent procedure on Chiron ACS automatic analyser
Free ß hCG - Solid phase 2 site immunoradiometric assay
Follow-up 100% karyotype
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Wenstrom 1999 (Continued)
Representative spectrum?
All tests
Yes High-risk referral for invasive testing
Acceptable reference standard?
All tests
Yes Amniocentesis
Partial veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Differential veriﬁcation avoided?
All tests
Yes All women received amniocentesis
Incorporation avoided?
All tests
Yes Index and reference standards separate
Reference standard results blinded?
All tests
Unclear No information given
Index test results blinded?
All tests
Unclear No information given
Relevant clinical information?
All tests
Yes Appropriate clinical information given
Uninterpretable results reported?
All tests
Yes None
Withdrawals explained?
All tests
Yes None
AFP: alpha-fetoprotein
CVS: chorionic villus sampling
hCG: human chorionic gonadotrophin
MoM: multiples of the median
NTD: neural tube defect
PAPP-A: pregnancy-associated plasma protein A
ProMBP: Proform of Eosinophil Major Basic Protein
uE3: unconjugated oestriol
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbas 1995 Unable to extract useful data.
Abdul-Hamid 2004 No Down’s syndrome pregnancies.
Abraha 1999 Unable to extract useful data.
Adekunle 1999 Unable to extract useful information.
Aitken 1993 Unable to extract useful data.
Aitken 1996a Fewer than 80% of pregnancies had gestational age conﬁrmed by USS
Aitken 1996b Fewer than 80% of pregnancies had gestational age conﬁrmed by USS
Akbas 2001 Less than 5 Down’s syndrome pregnancies.
Antona 1998 Likely fewer than 80% of pregnancies dated by USS.
Antsaklis 1999 Women screened at greater than 24 weeks gestation.
Ashwood 1987 Unable to extract useful data.
Asrani 2005 Review article.
Audibert 2001b Unable to ascertain whether part of screening population in Rozenberg et al. No response from authors
therefore excluded to reduce risk of data replication
Axt-Fleidner 2006 Unable to extract useful data.
Azuma 2002 Unable to extract useful data.
Baghagho 2004 Unable to obtain paper.
Bahado-Singh 1995 USS markers greater than 14 weeks gestation.
Bahado-Singh 1996 USS markers greater than 14 weeks gestation.
Bahado-Singh 1999b USS markers greater than 14 weeks gestation.
Bahado-Singh 2002 USS markers greater than 14 weeks gestation.
Bahado-Singh 2003 Review article.
Bar-Hava 2001 No Down’s pregnancies in study population.
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(Continued)
Barkai 1996 No Down’s pregnancies in study population.
Barnabei 1995 No Down’s pregnancies in study population.
Bartels 1988 Unable to extract useful data.
Bartels 1993 No Down’s pregnancies in study population.
Barth 1991 Second trimester ultrasound study.
Baviera 2004 Unclear method of conﬁrmation of gestational age.
Bazzett 1998 Male versus female fetuses.
Bellver 2005 No Down’s syndrome pregnancies in study.
Benn 1995 Less than 80% follow-up.
Benn 1996 Less than 80% follow-up.
Benn 1997 No Down’s pregnancies in study population.
Benn 1998 Less than 80% follow-up.
Benn 2001 Statistical modelling (computer simulation).
Benn 2002 Modelled data.
Benn 2003a Less than 80% of pregnancies dated by USS.
Benn 2003b Editorial.
Benn 2005a No Down’s pregnancies included.
Benn 2005b Mathematical model.
Berry 1995 Less than 80% of pregnancies USS dated.
Berry 1997 Less than 80% of pregnancies USS dated.
Bersinger 1994 Gestational age not USS estimated.
Bersinger 2000 Unable to extract useful data.
Bersinger 2001 No Down’s syndrome pregnancies in study population.
Bersinger 2003 Unable to extract useful data.
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(Continued)
Bersinger 2004 No Down’s syndrome pregnancies in study population.
Bersinger 2005 No Down’s syndrome pregnancies in study population.
Biggio 2004 Cost-effectiveness analysis.
Bindra 2002 Review article.
Blundell 1999 Unable to extract useful data.
Boots 1989 Population risk factor calculations.
Borruto 2002 Unable to extract useful data.
Boue 1990 Review article.
Bradley 1994 Screen negative population gestations not conﬁrmed by ultrasound
Braithwaite 1996 Review article.
Brambati 1995 USS screening inclusive of women greater than 14 weeks gestation
Brambati 1996 Review article.
Brizot 1995a Unable to extract useful data.
Brizot 1995b Unable to extract useful data.
Brizzi 1989b Second trimester ultrasound.
Brock 1990 Unable to extract useful data.
Campogrande 2001 Unable to extract useful data.
Canick 1988 Unable to extract useful data.
Canick 1995b Unable to extract useful data.
Canini 2002 No Down’s syndrome pregnancies in study population.
Cans 1998 Second trimester ultrasound.
Carreras 1991 Second trimester ultrasound.
Chen 1999 Review article.
Chen 2002 No Down’s syndrome pregnancies in study population.
Chen 2004 Less than 5 Down’s cases in study population.
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(Continued)
Chen 2005 Unable to extract useful data.
Cheng 1993 Likely that fewer than 80% of gestational age conﬁrmed by USS
Cheng 1999 Case series. No Down’s syndrome pregnancies in study population
Cheng 2004a No Down’s syndrome pregnancies in study population.
Cheng 2004b No Down’s syndrome pregnancies in study population.
Chitayat 2002 Less than 5 Down’s cases in study population.
Christiansen 2002 Unable to extract useful data.
Christiansen 2007 Unable to extract useful data.
Chung 2000 Less than 5 Down’s syndrome pregnancies in study population.
CNGOF 1996 Unable to obtain translation.
Cole 1996 Review article.
Comas 2001 USS at greater than 14 weeks.
Comas 2002a USS at greater than 14 weeks.
Comas 2002b USS at greater than 14 weeks.
Comstock 2006 Unable to extract useful data.
Conde 1998 Review article.
Crossley 1991 Less than 80% of pregnancies had gestational age conﬁrmation by ultrasound
Crossley 1993 Less than 80% of pregnancies had gestational age conﬁrmation by ultrasound
Crossley 1996 No Down’s syndrome pregnancies in study population.
Crossley 2002a Adjustment factors for smokers.
Cuckle 1984 Gestational age not conﬁrmed by USS.
Cuckle 1987a Gestational age not conﬁrmed by USS.
Cuckle 1987b No gestational age limits given.
Cuckle 1990 Paper presenting adjustment factors.
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(Continued)
Cuckle 1996 Data modelled on 4 meta-analysed studies.
Cuckle 1999a Unable to extract useful data.
Cuckle 1999b Review article.
Cullen 1990 Abnormal scans only in study population.
Cusick 2004 Less than 5 Down’s syndrome pregnancies in study population.
D’Ottavio 1997 Second trimester USS.
Dancoine 2001 No Down’s syndrome pregnancies in study population.
De Biasio 2000 Unable to extract useful information.
De Biasio, 1999 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Biasio, 2001 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Graaf 1991 Unable to extract useful data.
De Graaf 1999 Modelled data.
DeVore 2001 Second trimester ultrasound.
Dickerson 1994 Comment.
Dimaio 1987 Gestational age by USS only in screen positive population.
Doran 1986 Ultrasound conﬁrmation of gestational age performed in screen positive women only
Drugan 1996a Second trimester ultrasound.
Drugan 1996b Unable to extract useful data.
Drysdale 2002 Fewer than 5 Down’s syndrome pregnancies in population.
Ebell 1999 Review article.
Economides 1998 Unable to extract useful data.
Erickson 2004 No Down’s syndrome pregnancies in population.
Evans 1996 No Down’s syndrome pregnancies in population.
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(Continued)
Falcon 2005 Unable to extract useful data.
Falcon 2006 Unable to extract useful data.
Ford 1998 Audit.
Frishman 1997 No Down’s syndrome pregnancies in population.
Fukada 2000 Unable to extract useful data.
Ghidini 1998 Comparison of male versus female fetuses.
Goldie 1995 Fewer than 80% of study population ahd gestational age conﬁrmed by USS
Gonçalves 2004 Greater than 14 weeks USS screening.
Goodburn 1994 Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Grozdea 2002 Unable to extract useful data.
Gyselaers 2004a Less than 80% follow-up.
Gyselaers 2004b Less than 80% follow-up.
Gyselaers 2006a Unaffected pregnancies only.
Gyselaers 2006b Unable to extract useful data.
Hackshaw 1995 No Down’s syndrome pregnancies in population.
Hackshaw 2001 No Down’s syndrome pregnancies in population
Haddow 1992 Less than 80% of pregnancies had gestational age conﬁrmed by ultrasound scan
Hafner 1995 Less than 5 Down’s pregnancies in study population.
Hallahan 1998 Gestational age greater than 24 weeks.
Harrison 2006 Less than 80% of pregnancies had gestational age conﬁrmed by ultrasound scan
Harry 2006 Editorial.
Hayashi 1995 Unable to extract useful data.
Hayashi 1996 Less than 5 Down’s pregnancies in study population.
Heikkila 1997 Fewer than 80% of pregnancies had gestational age conﬁrmed by USS
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(Continued)
Heinonen 1996 No Down’s syndrome pregnancies in population.
Herman 2000 No Down’s syndrome pregnancies in study population.
Herman 2003 Correlation between markers, not evaluation of screening tests
Herrou 1992 Unable to extract useful data.
Hershey 1985 Gestation unclear.
Hershey 1986 Gestation based on LMP.
Hewitt 1993 Unable to extract useful data.
Hogdall 1992 Unclear method of determination of gestational age. Unable to extract useful data
Hong Kong Practitioner CME.
Howe 2000 Second trimester ultrasound scans.
Hsiao 1991 Unable to obtain translation.
Hsieh 1999 No Down’s syndrome pregnancies in study population.
Hsu 1997b Adjustment factors.
Hsu 1998a No Down’s syndrome pregnancies in study population.
Hsu 1999b No Down’s pregnancies.
Huang 2003 No Down’s syndrome pregnancies in study population.
Huggon 2004 Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003 No Down’s syndrome pregnancies in population.
Hui 2005 No Down’s syndrome pregnancies in population.
Hultén 2004 Editorial/commentary.
Hung 2003 Modelling.
Hurley 1993 Unable to extract useful data.
Huttly 2004 No Down’s syndrome pregnancies in population.
Hwa 2004 Less than 5 Down’s pregnancies in population.
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(Continued)
Iles 1996 Review.
Ind 1994 Unable to extract useful data.
Jean-Pierre 2005 Review article.
Johnson 1991 Gestatiojnal age estimated by USS in fewer than 80% of cases
Johnson 1993 Normal pregnancies only.
Jorgensen 1999 Gestation greater than 14 weeks for USS.
Josefsson 1998 No Down’s syndrome pregnancies in study population.
Jou 2001 Less than 5 Down’s syndrome pregnancies in study population.
Jun-Tao 2003 Unable to obtain translation.
Kagan 2006 Screen positive pregnancies only.
Kautzmann 1995 Fewer than 80% pregnancies had gestational age estimated by USS
Keith 1992 Summary article.
Kelekci 2004 Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995a Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995b Less than 80% follow-up. Unable to ascertain proportion of population with gestational age conﬁrmed
by USS
Kellner 1997 Assumption of normal karyotype without reference standard in signiﬁcant proportion of control preg-
nancies
Knight 1990 Review article.
Knight 2001 Validation of a speciﬁc assay.
Knight 2005 Less than 80% of pregnancies had gestational age conﬁrmed by ultrasound scan
Koos 2006 Review article.
Kornman 1996 Less than 5 Down’s syndrome pregnancies in population.
Kornman 1997 Unable to extract useful information.
Kramer 1998 No Down’s syndrome pregnancies in study population.
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(Continued)
Krantz 1996 Modelled data.
Krantz 2005 Adjustment factor.
Kulch 1993 No Down’s cases in population.
Lai 1998 Modelled population..
Lai 2003 No Down’s syndrome pregnancies in study population.
Laigaard 2006a Unable to extract useful data.
Laigaard 2006b Simulation.
Lam 1997 Unable to extract useful data.
Lam 1998 Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999a No Down’s syndrome pregnancies in population
Lam 1999b Unable to extract useful data
Lam 2000 Study of women’s decisions about screening.
Lam 2001 Male versus female fetuses.
Lambert-Messerlian 1996 Fewer than 80% of pregnancies USS dated.
Lambert-Messerlian 1998 Unable to extract useful data.
Lehavi 2005 Down’s syndrome pregnancies only.
Leung 2006 Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993 Appears to be a review article (French).
Li 1998 Unable to obtain translation.
Li 1999 Unable to obtain translation.
Liao 1997 Unable to obtain translation.
Liao 2001 Unable to extract useful data.
Lim 2002 Second trimester ultrasound.
Lippman 1987 Editorial.
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(Continued)
Lustig 1988 Gestational age by LMP only.
MacDonald 1991 Fewer than 80% of gestational ages estimated by USS.
Macintosh 1994 Unable to extract useful data.
Macintosh 1997 Unable to extract useful data.
Macri 1994 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998 Review article.
Malone 2003 Review article.
Mangione 2001 Abnormal screening results only.
Maymon 2001a No Down’s syndrome pregnancies in study population.
Maymon 2001b No normal test results included therefore unable to extract meaningful data
Maymon 2002 No Down’s syndrome pregnancies in study population.
Maymon 2004 No Down’s syndrome pregnancies in study population.
Maymon 2005 Modelled data.
McDufﬁe 1996 USS dating on screen positive women only.
Meier 2002 Observed vs expected cases of Down’s syndrome in a population
Merkatz 1984 Gestational age not conﬁrmed by ultrasound scan.
Merz 2005 Editorial.
Metzenbauer 2001 Normal pregnancies only.
Metzenbauer 2002 Unable to extract useful data.
Mikic 1999 No Down’s syndrome pregnancies in study population.
Miller 1991 Unable to extract useful data.
Milunsky 1989 Fewer than 80% gestational age estimated by USS.
Milunsky 1996 Fewer than 80% gestational age estimated by USS.
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(Continued)
Minobe 2002 Gestational age greater than speciﬁed limits.
Miyamura 1999 Unable to extract useful data.
Moghadam 1998 Unable to extract useful data.
Monni 2000 Less than 5 Down’s syndrome pregnancies.
Monni 2002 Review article.
Mooney 1994 Greater than 24 weeks gestation.
Muller 1994 No Down’s syndrome pregnancies in study population.
Muller 1996b Unable to extract useful data.
Muller 1999 Unable to extract useful data.
Muller 2002a Getstional age greater than 24 weeks.
Muller 2002b Unable to extract meaningful data - unable to separate double and triple test data
Muller 2003 No Down’s syndrome pregnancies in study population.
Murta 2002 Unable to extract useful data.
Musone 2000 Unable to extract useful data.
Musto 1986 Fewer than 80% USS dated.
Myrick 1990 Unable to extract useful data.
Neveux 1996a No Down’s syndrome pregnancies in population.
Neveux 1996b Unable to extract useful data.
Ng 2004 Unable to extract useful data.
Nicolaides 1992 Study of outcomes of abnormal NT results.
Nicolaides 2000 Review article.
Nicolaides 2004 Review article.
Nicolaides 2005a Unable to obtain translation - appears to be a review article
Nicolaides 2005b Unable to obtain translation - appears to be a review article
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(Continued)
Nicolaides 2005c Unable to obtain translation - appears to be a review article
Nicolaides 2005d Unable to obtain translation - appears to be a review article
Nicolaides 2005e Unable to obtain translation - appears to be a review article
Nicolaides 2005f Review article.
Niemimaa 2001 No Down’s pregnancies in study population.
Niemimaa 2002 No Down’s syndrome pregnancies in population.
Niemimaa 2003 No Down’s syndrome pregnancies in population.
Noble 1997 Unable to extract useful data.
Norgaard 1990 Less than 80% of gestational ages conﬁrmed by USS.
Norton 1992 Unable to extract useful data.
O’Brien 1997a No Down’s syndrome pregnancies in population.
O’Brien 1997b No Down’s syndrome pregnancies in population.
Odibo 2004 Gestational age of greater than 14 weeks in USS population.
Ognibene 1999 Unable to extract useful data.
Olajide 1989 Unable to extract useful data.
Onda 1996 Unable to extract useful data
Onda 1998 Unable to extract useful data.
Onda 2000 Less than 80% follow-up.
Orlandi 2002 No Down’s syndrome pregnancies in study population
Palka 1998 Twin data used in calculation of the median.
Palomaki 1989 Fewer than 80% USS dated.
Palomaki 1993 No Down’s syndrome pregnancies in population.
Palomaki 1994 No Down’s syndrome pregnancies in population.
Palomaki 1996 Meta-analysis.
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(Continued)
Palomaki 2005 Unable to extract meaningful data.
Panburana 2001 Less than 5 Down’s syndrome pregnancies in population.
Pandya 1994 Study of outcomes of abnormal NT results.
Pandya 1995 Review article.
Paul 2001 Unable to extract useful data.
Peralta 2005 Unable to extract useful data.
Perenc 1998 No Down’s syndrome pregnancies in study population.
Perheentupa 2002 No Down’s syndrome pregnancies in population.
Perona 1998 Smokers versus non smokers.
Petervari 2000 Unable to extract useful data.
Petrocik 1989 Likely fewer than 80% USS dated.
Phillips 1992 Gestational age conﬁrmed by USS in less than 80% of population
Phillips 1993 Gestational age conﬁrmed by USS in less than 80% of population
Pinette 2003 Women screened prior to recruitment.
Platt 2004 Unable to extract useful data.
Podobnik 1995 Abnormal results only.
Prefumo 2002 Comparison of prevalence and predicition.
Prefumo 2004 Comparison of a marker in women of different ethnic origins.
Price 1998 Unable to extract useful data.
Páez 2004 Unable to obtain translation.
Raty 2000 No Down’s syndrome pregnancies in population.
Rembouskos 2004 Unable to extract useful data.
Ren 1992 Review article.
Renier 1998 Method of ascertainment of gestational age unclear. Twin gestations included in general population
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(Continued)
Resta 1990 Second trimester USS.
Reynders 1997 Fewer than 5 Down’s cases.
Reynolds 1989 Explanation of mathematical techniques.
Reynolds 1999 Unable to extract useful data.
Ribbert 1996 No Down’s syndrome pregnancies in study population.
Rice 2005 Down’s syndrome pregnancies excluded from study.
Rich 1991 Unable to extract useful data.
Roberts 1995 No Down’s syndrome pregnancies in study population.
Robertson 1991 Editorial.
Rode 2003 No Down’s pregnancies.
Ronge 2006 Editorial - summary of FASTER results.
Rose 1995 Review article.
Ross 1997 Review article.
Rotmensch 1996 Unable to extract useful data.
Rotmensch 1999 No Down’s syndrome pregnancies in study population.
Rozenberg 2006 USS greater than 14 weeks gestation.
Rudnicka 2002 No Down’s syndrome pregnancies in population.
Ryall 1992 Unable to determine method of conﬁrmation of gestational age
Ryall 2001 High-risk results only included (i.e. no screen negative group for comparison)
Räty 2002 No Down’s pregnancies in population.
Sabriá 2002 Unable to ascertain hjow numbers calculated and from which populations
Sacchini 2003 Unable to extract useful data.
Saller 1997 Down’s syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001 No Down’s syndrome pregnancies in population.
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Salonen 1997 Fewer than 80% had gestational age estimated by USS.
Saltvedt 2005 Gestation greater than 14 weeks for nuchal scanning.
Saridogan 1996 Down’s syndrome and Edward’s syndrome affected pregnancies only
Savoldelli 1993 Unable to extract useful data.
Schiott 2006 Unable to extract useful data.
Schuchter 1998 No Down’s pregnancies in study population.
Scott 1995 Less than 5 Down’s syndrome pregnancies in study population.
Seeds 1990 Review article.
Seki 1995 No Down’s syndrome pregnancies in study population.
Shenhav 2003 No Down’s syndrome pregnancies.
Shintaku 1989 Unable to extract useful data.
Shulman 2003 No Down’s syndrome pregnancies in population.
Simon-Bouy 1999 Review article.
Simpson 1986 Gestational age conﬁrmed by USS in less than 80% of population
Smith 1990 Analysis of screen positive results.
Smith 1996 Review/meta-analysis.
Smith 1999 Unable to extract useful data.
Smith-Bindman 2001 Meta-analysis of second trimester ultrasound markers.
Smith-Bindman 2003 Population study, not examining DTA.
Snijders 1995 Study of prevalence, not screening.
Snijders 1999 Study of prevalence, not screening.
Soergel 2006 Less than 80% follow-up.
Sokol 1998 Observation of Down’s prevalence stratiﬁed by age.
Sonek 2003 Editorial.
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Spencer 1985 Fewer than 80% USS dated.
Spencer 1991a Likely fewer than 80% USS dated.
Spencer 1991b Unable to extract useful data.
Spencer 1992 Unable to extract useful data.
Spencer 1993a Fewer than 80% USS dated.
Spencer 1993b No Down’s pregnancies in study population.
Spencer 1993c Unable to extract useful data.
Spencer 1993d Fewer than 80% of pregnancies had gestational age conﬁrmed by USS
Spencer 1993e Unable to extract useful data.
Spencer 1995 No Down’s pregnancies in population.
Spencer 1996a Fewer than 80% of pregnancies had gestational age conﬁrmed by USS
Spencer 1997 Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a No Down’s pregnancies in population.
Spencer 1998b Unable to extract useful data.
Spencer 1999a Review.
Spencer 1999b Statistical methods paper.
Spencer 2000a Examination of median shifts rather than an evaluation of screening
Spencer 2000b No Down’s syndrome pregnancies in population.
Spencer 2000c No Down’s syndrome pregnancies in population.
Spencer 2000d No Down’s cases.
Spencer 2000e Male versus female fetuses.
Spencer 2000f No Down’s cases in population.
Spencer 2000g No Down’s pregnancies in population.
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Spencer 2000h No Down’s pregnancies in population.
Spencer 2000i Comparsison of fetal sex.
Spencer 2001 No Down’s syndrome pregnancies in population.
Spencer 2001a Unable to extract useful data.
Spencer 2001b Unable to extract useful data.
Spencer 2001c Unable to extract useful data.
Spencer 2001d No Down’s syndrome pregnancies in population.
Spencer 2002a No Down’s pregnancies.
Spencer 2002b Risk validation study.
Spencer 2002c No Down’s syndrome pregnancies in population.
Spencer 2002d Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a No Down’s pregnancies in population.
Spencer 2003b No Down’s pregnancies in population.
Spencer 2003c Calculation of weight correction factor.
Spencer 2003d Fewer than 5 Down’s syndrome pregnancies.
Spencer 2004 Calculation of smoking correction factor.
Spencer 2005a No Down’s pregnancies.
Spencer 2005b No Down’s pregnancies.
Spencer 2005c Comparison of two different assays - not actual screening evaluation
Spong 1999 Comparison of male and female fetuses.
Stevens 1998 Literature review.
Stoll 1992 Review article.
Su 2002a Unable to extract useful data.
Suchet 1995 Review article.
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Suchy 1990 Unable to ascertain method of conﬁrmation of gestational age
Summers 2003a Only 55% gestational ages estimated by USS.
Summers 2003b No Down’s syndrome pregnancies in study population.
Suntharasaj 2005 Examination of inter-observer variation in NT scanning.
Sutton 2004 Unable to extract useful data.
Suzuki 1998 Unable to extract useful data.
Tabor 1987 Geststional age not conﬁrmed by USS.
Tanski 1999 Information on screen positive pregnancies only.
Thilaganathan 1998 No Down’s syndrome pregnancies in study population.
Thilaganathan 1999 Editorial.
Tislaric 2002 No Down’s syndrome pregnancies in population.
Torok 1997 Unable to extract useful data.
Tsai 2001 Less than 5 Down’s syndrome pregnancies in study population.
Valerio 1996 Fewer than 80% pregnancies had gestational age estimated by USS
Van Blerk 1992 Unable to extract useful data.
Van Heesch, 2006 No Down’s syndrome pregnancies in study population. Software comparison study
Van Lith 1991 Unable to extract useful data.
Van Lith 1993 Unable to extract useful data.
Van Lith 1994 Unable to extract useful data.
Veress 1986 Unable to extract useful data.
Veress 1988 Unable to extract useful data.
Vintzileos 2003 Second trimester USS.
Wald 1988a Less than 80% had gestational age conﬁrmed by ultrasound.
Wald 1988b Gestational age not conﬁrmed by USS.
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Wald 1991 No Down’s pregnancies in study.
Wald 1992a Less than 80% had gestational age conﬁrmed by ultrasound.
Wald 1992b No Down’s pregnancies in study.
Wald 1992c No Down’s pregnancies in study.
Wald 1993 No USS dating.
Wald 1994a No Down’s syndrome pregnancies in population.
Wald 1994b Review article.
Wald 1996a No Down’s pregnancies.
Wald 1996b Dated by LMP.
Wald 1996d No Down’s syndrome pregnancies in population.
Wald 1996e Gestational age greater than 24 weeks.
Wald 1997 Data modelled on 3 separate populations of women.
Wald 1998 Unable to extract useful data.
Wald 1999a Unable to extract useful data.
Wald 1999b Gestational age not conﬁrmed by USS.
Wald 1999c No Down’s syndrome pregnancies.
Wald 1999d Modelled on several studies, some of which have no USS dating
Wald 2003b No cases.
Wald 2003c Less than 80% had gestational age conﬁrmed by USS.
Wald 2006 Modelled on SURRUS data.
Wallace 1994 Unable to extract useful data.
Wallace 1997 No Down’s syndrome pregnancies in study population.
Ward 2005 Review article.
Watt 1996a No Donw’s syndrome pregnancies in study population.
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(Continued)
Watt 1996b No Down’s syndrome pregnancies in study population.
Weinans 2001 Unable to extract useful data.
Weinans 2004 Study of women’s views on screening.
Welborn 1994 Abnormal results only (cystic hygroma).
Wenstrom 1993 Less than 80% of pregnancies had gestational age conﬁrmed by USS
Wenstrom 1995a Adjustment factors.
Wenstrom 1995b Less than 80% of pregnancies had gestational age conﬁrmed by USS
Whitlow 1998a Unable to extract useful data.
Whitlow 1998b Unable to extract useful data.
Whitlow 1999 Unable to extract useful data.
Williamson 1994 Likely fewer than 80% USS dated.
Wilson 2000 Review.
Wojdemann 2001 No Down’s syndrome pregnancies in study population.
Wong 2003 Less than 5 Down’s syndrome pregnancies in population.
Wright 2006 Mathematical model.
Yagel 1998 Second trimester USS.
Yamamoto 2001a Unable to extract useful data.
Yamamoto 2001b Method of determination of gestational age unclear.
Yamamoto 2001c Unable to extact useful data.
Yaron 2001 Male versus female fetuses.
Ye 1995 Unable to obtain translation.
Yoshida 2000 Fewer than 80% pregnancies had gestational age estimated by USS
Zeitune 1991 Only aneuploid pregnancies included in study.
Zelop 2005 No Down’s cases in population.
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Zhao 1998 Unable to obtain translation.
Zoppi 2003 Inappropriate study design.
LMP: last menstural period
USS: ultrasound screening
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Inhibin A at mixed cutpoints 4 1590
2 Inhibin A at 5% FPR 2 1192
3 Inhibin A at 2.4MoM 1 90
4 Inhibin A at 2 MoM 2 398
5 SP1 at mixed cutpoints 3 777
6 SP1 at 2.5MoM 1 325
7 SP1 at 5% FPR 2 452
8 AFP at mixed cutpoints 5 14201
9 AFP at 0.8MoM 1 3272
10 AFP at 5% FPR 3 9457
11 AFP at SD (speciﬁed in paper) 1 1472
12 Total hCG at 5% FPR 2 1192
13 Total hCG at 2.5MoM 1 246
14 Total hCG at mixed cutpoints 3 1438
15 Free ßhCG at 5% FPR 2 9357
16 uE3 at 5% FPR 2 1192
17 Troponin at 5% FPR 1 283
18 Free ßhCG to AFP ratio at 5%
FPR
1 8265
19 PAPP-A at 5% FPR 1 1092
20 PGF at 95th percentile 1 356
21 CA125 at 1.5MoM 1 328
22 Age and Total hCG at 5%
FPR/95th percentile
3 57257
23 Age and Total hCG at mixed
cutpoints
4 57768
24 Age and Total hCG at 1:384
risk
1 511
25 Age and AFP at 1:270 risk 1 3896
26 Age and AFP at 5% FPR 2 9357
27 Age and AFP at mixed
cutpoints
4 13764
28 Age and Free ßhCG at mixed
cutpoints
4 14985
29 Age and Free ßhCG at 1:384
risk
1 511
30 Age and uE3 at mixed cutpoints 2 1603
31 Age and uE3 at 1:384 risk 1 511
32 Age and Free ßhCG to AFP at
5% FPR
1 8265
33 Age and inhibin at 5% FPR 2 1117
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34 Age and PAPP-A at 5% FPR 2 1117
35 Age and ProMBP at 1:250 risk 1 256
36 Age and Free αhCG at 1:384
risk
1 511
37 Age, Total hCG and Free
ßhCG at 1:384 risk
1 511
38 Age, Total hCG and uE3 at 5%
FPR
1 370
39 Age, Total hCG and uE3 at
1:384 risk
1 511
40 Age, Total hCG and uE3 at
mixed cutpoints
2 881
41 Age, Total hCG and AFP at
5% FPR
4 22816
42 Age, Total hCG and AFP at
1:250 risk
6 43519
43 Age, Total hCG and AFP at
mixed cutpoints
15 133783
44 Age, Total hCG and SP1at 5%
FPR
1 370
45 Age, Total hCG and Free
αhCG at 1:384 risk
1 511
46 Age, Free ßhCG and uE3 at
1:384 risk
1 511
47 Age, Free ßhCG and AFP at
1:250 risk
3 15912
48 Age, Free ßhCG and AFP at
5% FPR
5 23979
49 Age, Free ßhCG and AFP at
mixed cutpoints
12 45597
50 Age, Free ßhCG and Free
αhCG at 1:384 risk
1 511
51 Age, AFP and uE3 at 1:384 risk 1 511
52 Age, AFP and uE3 at 5% FPR 1 370
53 Age, AFP and uE3 at mixed
cutpoints
2 881
54 Age, uE3 and Free αhCG at
1:384 risk
1 511
55 Age, uE3 and SP1 at 5% FPR 1 370
56 Age, AFP and SP1 at 5% FPR 1 370
57 Age, AFP and
Hyperglycosylated hCG at 5%
FPR
1 328
58 Age, AFP and Free αhCG
1:384 risk
1 511
59 Age, Total hCG, Free ßhCG
and AFP at 1:266 risk
1 344
60 Age, Total hCG, AFP and uE3
at 5% FPR
7 15453
61 Age, Total hCG, AFP and uE3
at 1:250 risk
5 30910
158Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
62 Age, Total hCG, AFP and uE3
at mixed cutpoints
24 89047
63 Age, Total hCG, uE3 and SP1
at 5% FPR
1 370
64 Age, Total hCG, AFP and
Inhibin A at 1:190 risk
2 564
65 Age, Total hCG, AFP and
Inhibin A at 1:250 risk
1 218
66 Age, Total hCG, AFP and SP1
at 5% FPR
1 370
67 Age, Total hCG, AFP and
CA125 at 1:190 risk
1 328
68 Age, Free ßhCG, AFP and uE3
at 5% FPR
3 6430
69 Age, Free ßhCG, AFP and uE3
at 1:250 risk
2 1809
70 Age, Free ßhCG, AFP and uE3
at mixed cutpoints
7 10541
71 Age, Free ßhCG, AFP and
Inhibin A at 1:190 risk
1 1256
72 Age, Free ßhCG, AFP and
ProMBP at 5% FPR
1 334
73 Age, Free ßhCG, AFP and
ProMBP at 1:250 risk
1 334
74 Age, AFP, uE3 and Free αhCG
at 1:384 risk
1 511
75 Age, AFP, uE3 and Inhibin A at
1:233 risk
1 346
76 Age, AFP, uE3 and SP1 at 5%
FPR
1 370
77 Age, Total hCG, Free ßhCG,
AFP and uE3 at 1:384 risk
1 511
78 Age, Total hCG, AFP, uE3 and
Inhibin A at 5% FPR
1 1092
79 Age, Total hCG, AFP, uE3 and
Inhibin A at 1:150 risk
3 2014
80 Age, Total hCG, AFP, uE3 and
Inhibin A at 1:250 risk
2 758
81 Age, Total hCG, AFP, uE3 and
Inhibin A at mixed cutpoints
5 38342
82 Age, Total hCG, AFP, uE3 and
Free αhCG at 1:384 risk
1 511
83 Age, Total hCG, AFP, uE3 and
SP1 at 5% FPR
1 370
84 Age, Free ßhCG, AFP, uE3 and
Inhibin A at 5% FPR
1 1092
85 Age, Free ßhCG, AFP, uE3 and
Inhibin A at 1:250 risk
1 1092
86 Age, Free ßhCG, AFP, uE3 and
Inhibin A at mixed cutpoints
2 2348
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87 Age, Total hCG, AFP, uE3,
Inhibin A and PAPP-A at 5%
FPR
1 1092
88 Age, Total hCG, Free ßhCG,
AFP, uE3 and Free αhCG at
1:384 risk
1 511
89 Age, Free ßhCG, AFP, uE3,
Inhibin A and PAPP-A at
5%FPR
1 1092
Test 1. Inhibin A at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 1 Inhibin A at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Haddow 1998 27 21 25 235 0.52 [ 0.38, 0.66 ] 0.92 [ 0.88, 0.95 ]
Pandian 2004 5 4 11 80 0.31 [ 0.11, 0.59 ] 0.95 [ 0.88, 0.99 ]
Van Lith 1992 5 8 5 72 0.50 [ 0.19, 0.81 ] 0.90 [ 0.81, 0.96 ]
Wald 2003a 48 51 34 959 0.59 [ 0.47, 0.69 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Inhibin A at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 2 Inhibin A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pandian 2004 5 4 11 80 0.31 [ 0.11, 0.59 ] 0.95 [ 0.88, 0.99 ]
Wald 2003a 48 51 34 959 0.59 [ 0.47, 0.69 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Inhibin A at 2.4MoM.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 3 Inhibin A at 2.4MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Van Lith 1992 4 4 6 76 0.40 [ 0.12, 0.74 ] 0.95 [ 0.88, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Inhibin A at 2 MoM.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 4 Inhibin A at 2 MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Haddow 1998 27 21 25 235 0.52 [ 0.38, 0.66 ] 0.92 [ 0.88, 0.95 ]
Van Lith 1992 5 8 5 72 0.50 [ 0.19, 0.81 ] 0.90 [ 0.81, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. SP1 at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 5 SP1 at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1990 4 0 39 282 0.09 [ 0.03, 0.22 ] 1.00 [ 0.99, 1.00 ]
Pandian 2004 13 4 3 80 0.81 [ 0.54, 0.96 ] 0.95 [ 0.88, 0.99 ]
Qin 1997 21 12 95 224 0.18 [ 0.12, 0.26 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. SP1 at 2.5MoM.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 6 SP1 at 2.5MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1990 7 4 36 278 0.16 [ 0.07, 0.31 ] 0.99 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 7 SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pandian 2004 13 4 3 80 0.81 [ 0.54, 0.96 ] 0.95 [ 0.88, 0.99 ]
Qin 1997 21 12 95 224 0.18 [ 0.12, 0.26 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. AFP at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 8 AFP at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brizzi 1989a 12 231 15 1214 0.44 [ 0.25, 0.65 ] 0.84 [ 0.82, 0.86 ]
Greenberg 1991 37 1405 14 1816 0.73 [ 0.58, 0.84 ] 0.56 [ 0.55, 0.58 ]
Hsu 1997a 8 411 39 7807 0.17 [ 0.08, 0.31 ] 0.95 [ 0.95, 0.95 ]
Pandian 2004 5 4 11 80 0.31 [ 0.11, 0.59 ] 0.95 [ 0.88, 0.99 ]
Wald 2003a 20 51 62 959 0.24 [ 0.16, 0.35 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. AFP at 0.8MoM.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 9 AFP at 0.8MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Greenberg 1991 37 1405 14 1816 0.73 [ 0.58, 0.84 ] 0.56 [ 0.55, 0.58 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. AFP at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 10 AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1997a 8 411 39 7807 0.17 [ 0.08, 0.31 ] 0.95 [ 0.95, 0.95 ]
Pandian 2004 5 4 11 80 0.31 [ 0.11, 0.59 ] 0.95 [ 0.88, 0.99 ]
Wald 2003a 20 51 62 959 0.24 [ 0.16, 0.35 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. AFP at SD (specified in paper).
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 11 AFP at SD (specified in paper)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brizzi 1989a 12 231 15 1214 0.44 [ 0.25, 0.65 ] 0.84 [ 0.82, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Total hCG at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 12 Total hCG at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pandian 2004 4 4 12 80 0.25 [ 0.07, 0.52 ] 0.95 [ 0.88, 0.99 ]
Wald 2003a 33 51 49 959 0.40 [ 0.30, 0.52 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. Total hCG at 2.5MoM.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 13 Total hCG at 2.5MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1990 13 12 30 191 0.30 [ 0.17, 0.46 ] 0.94 [ 0.90, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 14. Total hCG at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 14 Total hCG at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1990 8 3 35 200 0.19 [ 0.08, 0.33 ] 0.99 [ 0.96, 1.00 ]
Pandian 2004 4 4 12 80 0.25 [ 0.07, 0.52 ] 0.95 [ 0.88, 0.99 ]
Wald 2003a 33 51 49 959 0.40 [ 0.30, 0.52 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. Free ßhCG at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 15 Free ??hCG at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1997a 22 411 25 7807 0.47 [ 0.32, 0.62 ] 0.95 [ 0.95, 0.95 ]
Wald 2003a 41 51 41 959 0.50 [ 0.39, 0.61 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. uE3 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 16 uE3 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pandian 2004 12 4 4 80 0.75 [ 0.48, 0.93 ] 0.95 [ 0.88, 0.99 ]
Wald 2003a 33 51 49 959 0.40 [ 0.30, 0.52 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 17. Troponin at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 17 Troponin at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2004 18 12 27 226 0.40 [ 0.26, 0.56 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. Free ßhCG to AFP ratio at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 18 Free ??hCG to AFP ratio at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1997a 22 411 25 7807 0.47 [ 0.32, 0.62 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. PAPP-A at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 19 PAPP-A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 4 51 78 959 0.05 [ 0.01, 0.12 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
166Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 20. PGF at 95th percentile.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 20 PGF at 95th percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Su 2002 7 16 29 304 0.19 [ 0.08, 0.36 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. CA125 at 1.5MoM.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 21 CA125 at 1.5MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wenstrom 1997b 10 43 12 263 0.45 [ 0.24, 0.68 ] 0.86 [ 0.82, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Age and Total hCG at 5% FPR/95th percentile.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 22 Age and Total hCG at 5% FPR/95th percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Knight 1998 23 253 29 4812 0.44 [ 0.30, 0.59 ] 0.95 [ 0.94, 0.96 ]
Muller 1996a 93 5562 42 45351 0.69 [ 0.60, 0.77 ] 0.89 [ 0.89, 0.89 ]
Wald 2003a 43 51 39 959 0.52 [ 0.41, 0.64 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. Age and Total hCG at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 23 Age and Total hCG at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 6 67 5 433 0.55 [ 0.23, 0.83 ] 0.87 [ 0.83, 0.89 ]
Knight 1998 23 253 29 4812 0.44 [ 0.30, 0.59 ] 0.95 [ 0.94, 0.96 ]
Muller 1996a 93 5562 42 45351 0.69 [ 0.60, 0.77 ] 0.89 [ 0.89, 0.89 ]
Wald 2003a 43 51 39 959 0.52 [ 0.41, 0.64 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Age and Total hCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 24 Age and Total hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 6 67 5 433 0.55 [ 0.23, 0.83 ] 0.87 [ 0.83, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Age and AFP at 1:270 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 25 Age and AFP at 1:270 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rose 1994 28 2398 5 1465 0.85 [ 0.68, 0.95 ] 0.38 [ 0.36, 0.39 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 26. Age and AFP at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 26 Age and AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1997a 20 411 27 7807 0.43 [ 0.28, 0.58 ] 0.95 [ 0.95, 0.95 ]
Wald 2003a 34 51 48 959 0.41 [ 0.31, 0.53 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. Age and AFP at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 27 Age and AFP at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 45 3 455 0.73 [ 0.39, 0.94 ] 0.91 [ 0.88, 0.93 ]
Hsu 1997a 20 411 27 7807 0.43 [ 0.28, 0.58 ] 0.95 [ 0.95, 0.95 ]
Rose 1994 28 2398 5 1465 0.85 [ 0.68, 0.95 ] 0.38 [ 0.36, 0.39 ]
Wald 2003a 34 51 48 959 0.41 [ 0.31, 0.53 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. Age and Free ßhCG at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 28 Age and Free ??hCG at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 82 3 418 0.73 [ 0.39, 0.94 ] 0.84 [ 0.80, 0.87 ]
Hsu 1997a 28 411 19 7807 0.60 [ 0.44, 0.74 ] 0.95 [ 0.95, 0.95 ]
Knight 1998 19 253 33 4812 0.37 [ 0.24, 0.51 ] 0.95 [ 0.94, 0.96 ]
Wald 2003a 50 51 32 959 0.61 [ 0.50, 0.72 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. Age and Free ßhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 29 Age and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 82 3 418 0.73 [ 0.39, 0.94 ] 0.84 [ 0.80, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. Age and uE3 at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 30 Age and uE3 at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 9 64 2 436 0.82 [ 0.48, 0.98 ] 0.87 [ 0.84, 0.90 ]
Wald 2003a 43 51 39 959 0.52 [ 0.41, 0.64 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. Age and uE3 at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 31 Age and uE3 at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 9 64 2 436 0.82 [ 0.48, 0.98 ] 0.87 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 32. Age and Free ßhCG to AFP at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 32 Age and Free ??hCG to AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1997a 29 411 18 7807 0.62 [ 0.46, 0.75 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. Age and inhibin at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 33 Age and inhibin at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 48 51 34 959 0.59 [ 0.47, 0.69 ] 0.95 [ 0.93, 0.96 ]
Watanabe 2002 3 1 2 19 0.60 [ 0.15, 0.95 ] 0.95 [ 0.75, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 34. Age and PAPP-A at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 34 Age and PAPP-A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 27 51 55 959 0.33 [ 0.23, 0.44 ] 0.95 [ 0.93, 0.96 ]
Watanabe 2002 3 1 2 19 0.60 [ 0.15, 0.95 ] 0.95 [ 0.75, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Age and ProMBP at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 35 Age and ProMBP at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 1999 51 8 54 143 0.49 [ 0.39, 0.59 ] 0.95 [ 0.90, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 36. Age and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 36 Age and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 56 3 444 0.73 [ 0.39, 0.94 ] 0.89 [ 0.86, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 37. Age, Total hCG and Free ßhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 37 Age, Total hCG and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 6 88 5 412 0.55 [ 0.23, 0.83 ] 0.82 [ 0.79, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 38. Age, Total hCG and uE3 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 38 Age, Total hCG and uE3 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 24 16 26 304 0.48 [ 0.34, 0.63 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Age, Total hCG and uE3 at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 39 Age, Total hCG and uE3 at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 9 66 2 434 0.82 [ 0.48, 0.98 ] 0.87 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
173Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 40. Age, Total hCG and uE3 at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 40 Age, Total hCG and uE3 at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 24 16 26 304 0.48 [ 0.34, 0.63 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 9 66 2 434 0.82 [ 0.48, 0.98 ] 0.87 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. Age, Total hCG and AFP at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 41 Age, Total hCG and AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 25 16 25 304 0.50 [ 0.36, 0.64 ] 0.95 [ 0.92, 0.97 ]
Knight 1998 30 253 22 4812 0.58 [ 0.43, 0.71 ] 0.95 [ 0.94, 0.96 ]
Lam 2002 26 810 9 15392 0.74 [ 0.57, 0.88 ] 0.95 [ 0.95, 0.95 ]
Wald 2003a 54 51 28 959 0.66 [ 0.55, 0.76 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. Age, Total hCG and AFP at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 42 Age, Total hCG and AFP at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001a 6 124 4 3656 0.60 [ 0.26, 0.88 ] 0.97 [ 0.96, 0.97 ]
Beekhuis 1993 5 149 1 2127 0.83 [ 0.36, 1.00 ] 0.93 [ 0.92, 0.94 ]
Benattar 1999 4 73 1 1571 0.80 [ 0.28, 0.99 ] 0.96 [ 0.94, 0.97 ]
David 1996 31 378 16 9075 0.66 [ 0.51, 0.79 ] 0.96 [ 0.96, 0.96 ]
Debieve 2000 11 15 7 185 0.61 [ 0.36, 0.83 ] 0.93 [ 0.88, 0.96 ]
Roberts 2000 31 1323 10 24716 0.76 [ 0.60, 0.88 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Age, Total hCG and AFP at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 43 Age, Total hCG and AFP at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001a 6 124 4 3656 0.60 [ 0.26, 0.88 ] 0.97 [ 0.96, 0.97 ]
Bartels 1994a 25 16 25 304 0.50 [ 0.36, 0.64 ] 0.95 [ 0.92, 0.97 ]
Beekhuis 1993 5 149 1 2127 0.83 [ 0.36, 1.00 ] 0.93 [ 0.92, 0.94 ]
Benattar 1999 4 73 1 1571 0.80 [ 0.28, 0.99 ] 0.96 [ 0.94, 0.97 ]
Crossley 1994 26 1497 11 28550 0.70 [ 0.53, 0.84 ] 0.95 [ 0.95, 0.95 ]
David 1996 31 378 16 9075 0.66 [ 0.51, 0.79 ] 0.96 [ 0.96, 0.96 ]
Debieve 2000 11 15 7 185 0.61 [ 0.36, 0.83 ] 0.93 [ 0.88, 0.96 ]
Forest 1995 9 57 2 443 0.82 [ 0.48, 0.98 ] 0.89 [ 0.85, 0.91 ]
Jou 2000 10 1144 6 16582 0.63 [ 0.35, 0.85 ] 0.94 [ 0.93, 0.94 ]
Knight 1998 30 253 22 4812 0.58 [ 0.43, 0.71 ] 0.95 [ 0.94, 0.96 ]
Lam 2002 26 810 9 15392 0.74 [ 0.57, 0.88 ] 0.95 [ 0.95, 0.95 ]
Lemay 1995 21 1013 11 17555 0.66 [ 0.47, 0.81 ] 0.95 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Milunsky 1993 24 36 7 444 0.77 [ 0.59, 0.90 ] 0.93 [ 0.90, 0.95 ]
Roberts 2000 31 1323 10 24716 0.76 [ 0.60, 0.88 ] 0.95 [ 0.95, 0.95 ]
Wald 2003a 54 51 28 959 0.66 [ 0.55, 0.76 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 44. Age, Total hCG and SP1at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 44 Age, Total hCG and SP1at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 22 16 28 304 0.44 [ 0.30, 0.59 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Age, Total hCG and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 45 Age, Total hCG and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 9 69 2 431 0.82 [ 0.48, 0.98 ] 0.86 [ 0.83, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. Age, Free ßhCG and uE3 at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 46 Age, Free ??hCG and uE3 at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 86 3 414 0.73 [ 0.39, 0.94 ] 0.83 [ 0.79, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Age, Free ßhCG and AFP at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 47 Age, Free ??hCG and AFP at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brajenovic 1998 7 255 2 2924 0.78 [ 0.40, 0.97 ] 0.92 [ 0.91, 0.93 ]
Kadir 1999 11 418 2 3996 0.85 [ 0.55, 0.98 ] 0.91 [ 0.90, 0.91 ]
Rozenberg 2002 14 645 6 7632 0.70 [ 0.46, 0.88 ] 0.92 [ 0.92, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. Age, Free ßhCG and AFP at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 48 Age, Free ??hCG and AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Anandakumar 1999 4 60 3 1141 0.57 [ 0.18, 0.90 ] 0.95 [ 0.94, 0.96 ]
Hsu 1997a 30 411 17 7807 0.64 [ 0.49, 0.77 ] 0.95 [ 0.95, 0.95 ]
Knight 1998 26 253 26 4812 0.50 [ 0.36, 0.64 ] 0.95 [ 0.94, 0.96 ]
Rozenberg 2002 12 414 8 7863 0.60 [ 0.36, 0.81 ] 0.95 [ 0.95, 0.95 ]
Wald 2003a 58 51 24 959 0.71 [ 0.60, 0.80 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. Age, Free ßhCG and AFP at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 49 Age, Free ??hCG and AFP at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Anandakumar 1999 4 60 3 1141 0.57 [ 0.18, 0.90 ] 0.95 [ 0.94, 0.96 ]
Brajenovic 1998 7 255 2 2924 0.78 [ 0.40, 0.97 ] 0.92 [ 0.91, 0.93 ]
Chao 1999 12 804 3 9279 0.80 [ 0.52, 0.96 ] 0.92 [ 0.91, 0.93 ]
Extermann 1998 14 120 9 2396 0.61 [ 0.39, 0.80 ] 0.95 [ 0.94, 0.96 ]
Forest 1995 9 67 2 433 0.82 [ 0.48, 0.98 ] 0.87 [ 0.83, 0.89 ]
Hsu 1997a 30 411 17 7807 0.64 [ 0.49, 0.77 ] 0.95 [ 0.95, 0.95 ]
Kadir 1999 11 418 2 3996 0.85 [ 0.55, 0.98 ] 0.91 [ 0.90, 0.91 ]
Knight 1998 26 253 26 4812 0.50 [ 0.36, 0.64 ] 0.95 [ 0.94, 0.96 ]
Milunsky 1993 23 26 8 454 0.74 [ 0.55, 0.88 ] 0.95 [ 0.92, 0.96 ]
Rozenberg 2002 14 645 6 7632 0.70 [ 0.46, 0.88 ] 0.92 [ 0.92, 0.93 ]
Wald 2003a 58 51 24 959 0.71 [ 0.60, 0.80 ] 0.95 [ 0.93, 0.96 ]
Wenstrom 1997a 27 63 4 250 0.87 [ 0.70, 0.96 ] 0.80 [ 0.75, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 50. Age, Free ßhCG and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 50 Age, Free ??hCG and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 64 3 436 0.73 [ 0.39, 0.94 ] 0.87 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. Age, AFP and uE3 at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 51 Age, AFP and uE3 at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 8 62 3 438 0.73 [ 0.39, 0.94 ] 0.88 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 52. Age, AFP and uE3 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 52 Age, AFP and uE3 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 15 16 35 304 0.30 [ 0.18, 0.45 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 53. Age, AFP and uE3 at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 53 Age, AFP and uE3 at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 15 16 35 304 0.30 [ 0.18, 0.45 ] 0.95 [ 0.92, 0.97 ]
Forest 1995 8 62 3 438 0.73 [ 0.39, 0.94 ] 0.88 [ 0.84, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. Age, uE3 and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 54 Age, uE3 and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 9 75 2 425 0.82 [ 0.48, 0.98 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 55. Age, uE3 and SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 55 Age, uE3 and SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 18 16 32 304 0.36 [ 0.23, 0.51 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 56. Age, AFP and SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 56 Age, AFP and SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 17 16 33 304 0.34 [ 0.21, 0.49 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 57. Age, AFP and Hyperglycosylated hCG at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 57 Age, AFP and Hyperglycosylated hCG at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Talbot 2003 27 14 23 264 0.54 [ 0.39, 0.68 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 58. Age, AFP and Free αhCG 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 58 Age, AFP and Free ??hCG 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 9 74 2 426 0.82 [ 0.48, 0.98 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 59. Age, Total hCG, Free ßhCG and AFP at 1:266 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 59 Age, Total hCG, Free ??hCG and AFP at 1:266 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wenstrom 1997a 27 56 4 257 0.87 [ 0.70, 0.96 ] 0.82 [ 0.77, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 60. Age, Total hCG, AFP and uE3 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 60 Age, Total hCG, AFP and uE3 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 7 30 14 875 0.33 [ 0.15, 0.57 ] 0.97 [ 0.95, 0.98 ]
Bahado-Singh 2000 17 117 29 2228 0.37 [ 0.23, 0.52 ] 0.95 [ 0.94, 0.96 ]
Bartels 1994a 25 16 25 304 0.50 [ 0.36, 0.64 ] 0.95 [ 0.92, 0.97 ]
Haddow 1994 32 264 22 5018 0.59 [ 0.45, 0.72 ] 0.95 [ 0.94, 0.96 ]
Knight 1998 30 253 22 4812 0.58 [ 0.43, 0.71 ] 0.95 [ 0.94, 0.96 ]
Sancken 2003 18 8 15 180 0.55 [ 0.36, 0.72 ] 0.96 [ 0.92, 0.98 ]
Wald 2003a 61 51 21 959 0.74 [ 0.64, 0.83 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 61. Age, Total hCG, AFP and uE3 at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 61 Age, Total hCG, AFP and uE3 at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
David 1996 27 372 20 8939 0.57 [ 0.42, 0.72 ] 0.96 [ 0.96, 0.96 ]
Debieve 2000 14 15 4 185 0.78 [ 0.52, 0.94 ] 0.93 [ 0.88, 0.96 ]
Mancini 1991 9 170 0 552 1.00 [ 0.66, 1.00 ] 0.76 [ 0.73, 0.80 ]
Piggott 1994 8 203 3 6776 0.73 [ 0.39, 0.94 ] 0.97 [ 0.97, 0.97 ]
Ward 1999 12 673 4 12924 0.75 [ 0.48, 0.93 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 62. Age, Total hCG, AFP and uE3 at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 62 Age, Total hCG, AFP and uE3 at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 7 30 14 875 0.33 [ 0.15, 0.57 ] 0.97 [ 0.95, 0.98 ]
Bahado-Singh 2000 17 117 29 2228 0.37 [ 0.23, 0.52 ] 0.95 [ 0.94, 0.96 ]
Bartels 1994a 25 16 25 304 0.50 [ 0.36, 0.64 ] 0.95 [ 0.92, 0.97 ]
Bartels 1994b 8 315 2 330 0.80 [ 0.44, 0.97 ] 0.51 [ 0.47, 0.55 ]
David 1996 27 372 20 8939 0.57 [ 0.42, 0.72 ] 0.96 [ 0.96, 0.96 ]
Debieve 2000 14 15 4 185 0.78 [ 0.52, 0.94 ] 0.93 [ 0.88, 0.96 ]
Extermann 1998 15 137 8 2379 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.95 ]
Forest 1995 9 68 2 432 0.82 [ 0.48, 0.98 ] 0.86 [ 0.83, 0.89 ]
Haddow 1994 48 1321 6 3961 0.89 [ 0.77, 0.96 ] 0.75 [ 0.74, 0.76 ]
Heyl 1990 12 19 4 66 0.75 [ 0.48, 0.93 ] 0.78 [ 0.67, 0.86 ]
Huderer-Duric 2000 10 852 2 1969 0.83 [ 0.52, 0.98 ] 0.70 [ 0.68, 0.71 ]
Kishida 2000 10 368 0 677 1.00 [ 0.69, 1.00 ] 0.65 [ 0.62, 0.68 ]
Knight 1998 30 253 22 4812 0.58 [ 0.43, 0.71 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mancini 1991 9 170 0 552 1.00 [ 0.66, 1.00 ] 0.76 [ 0.73, 0.80 ]
Perona 1997 33 2031 8 18784 0.80 [ 0.65, 0.91 ] 0.90 [ 0.90, 0.91 ]
Piggott 1994 8 203 3 6776 0.73 [ 0.39, 0.94 ] 0.97 [ 0.97, 0.97 ]
Rosen 2002 13 424 0 569 1.00 [ 0.75, 1.00 ] 0.57 [ 0.54, 0.60 ]
Sancken 2003 26 23 7 165 0.79 [ 0.61, 0.91 ] 0.88 [ 0.82, 0.92 ]
Suzumori 1997 12 208 2 856 0.86 [ 0.57, 0.98 ] 0.80 [ 0.78, 0.83 ]
Verloes 1995 11 841 4 9594 0.73 [ 0.45, 0.92 ] 0.92 [ 0.91, 0.92 ]
Wald 2003a 61 51 21 959 0.74 [ 0.64, 0.83 ] 0.95 [ 0.93, 0.96 ]
Ward 1999 12 673 4 12924 0.75 [ 0.48, 0.93 ] 0.95 [ 0.95, 0.95 ]
Wenstrom 1997a 27 75 4 238 0.87 [ 0.70, 0.96 ] 0.76 [ 0.71, 0.81 ]
Wenstrom 1999 9 249 4 994 0.69 [ 0.39, 0.91 ] 0.80 [ 0.78, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 63. Age, Total hCG, uE3 and SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 63 Age, Total hCG, uE3 and SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 22 16 28 304 0.44 [ 0.30, 0.59 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 64. Age, Total hCG, AFP and Inhibin A at 1:190 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 64 Age, Total hCG, AFP and Inhibin A at 1:190 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Debieve 2000 15 11 3 189 0.83 [ 0.59, 0.96 ] 0.95 [ 0.90, 0.97 ]
Wenstrom 1997 30 47 3 266 0.91 [ 0.76, 0.98 ] 0.85 [ 0.81, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 65. Age, Total hCG, AFP and Inhibin A at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 65 Age, Total hCG, AFP and Inhibin A at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Debieve 2000 16 13 2 187 0.89 [ 0.65, 0.99 ] 0.94 [ 0.89, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 66. Age, Total hCG, AFP and SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 66 Age, Total hCG, AFP and SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 25 16 25 304 0.50 [ 0.36, 0.64 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 67. Age, Total hCG, AFP and CA125 at 1:190 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 67 Age, Total hCG, AFP and CA125 at 1:190 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wenstrom 1997b 18 48 4 258 0.82 [ 0.60, 0.95 ] 0.84 [ 0.80, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 68. Age, Free ßhCG, AFP and uE3 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 68 Age, Free ??hCG, AFP and uE3 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Knight 1998 27 253 25 4812 0.52 [ 0.38, 0.66 ] 0.95 [ 0.94, 0.96 ]
Sancken 2003 21 6 12 182 0.64 [ 0.45, 0.80 ] 0.97 [ 0.93, 0.99 ]
Wald 2003a 63 51 19 959 0.77 [ 0.66, 0.85 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 69. Age, Free ßhCG, AFP and uE3 at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 69 Age, Free ??hCG, AFP and uE3 at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cioffi 2000 15 4 2 696 0.88 [ 0.64, 0.99 ] 0.99 [ 0.99, 1.00 ]
Wald 2003a 66 70 16 940 0.80 [ 0.70, 0.88 ] 0.93 [ 0.91, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
186Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 70. Age, Free ßhCG, AFP and uE3 at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 70 Age, Free ??hCG, AFP and uE3 at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cioffi 2000 15 4 2 696 0.88 [ 0.64, 0.99 ] 0.99 [ 0.99, 1.00 ]
Extermann 1998 15 123 8 2393 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Forest 1995 8 73 3 427 0.73 [ 0.39, 0.94 ] 0.85 [ 0.82, 0.88 ]
Knight 1998 27 253 25 4812 0.52 [ 0.38, 0.66 ] 0.95 [ 0.94, 0.96 ]
Sancken 2003 23 18 10 170 0.70 [ 0.51, 0.84 ] 0.90 [ 0.85, 0.94 ]
Wald 2003a 66 70 16 940 0.80 [ 0.70, 0.88 ] 0.93 [ 0.91, 0.95 ]
Wenstrom 1997a 29 59 2 254 0.94 [ 0.79, 0.99 ] 0.81 [ 0.76, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 71. Age, Free ßhCG, AFP and Inhibin A at 1:190 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 71 Age, Free ??hCG, AFP and Inhibin A at 1:190 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wenstrom 1999 8 249 5 994 0.62 [ 0.32, 0.86 ] 0.80 [ 0.78, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 72. Age, Free ßhCG, AFP and ProMBP at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 72 Age, Free ??hCG, AFP and ProMBP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2004 64 11 43 216 0.60 [ 0.50, 0.69 ] 0.95 [ 0.91, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 73. Age, Free ßhCG, AFP and ProMBP at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 73 Age, Free ??hCG, AFP and ProMBP at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2004 66 12 41 215 0.62 [ 0.52, 0.71 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 74. Age, AFP, uE3 and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 74 Age, AFP, uE3 and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 11 111 0 389 1.00 [ 0.72, 1.00 ] 0.78 [ 0.74, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 75. Age, AFP, uE3 and Inhibin A at 1:233 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 75 Age, AFP, uE3 and Inhibin A at 1:233 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wenstrom 1997 29 66 4 247 0.88 [ 0.72, 0.97 ] 0.79 [ 0.74, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 76. Age, AFP, uE3 and SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 76 Age, AFP, uE3 and SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 19 16 31 304 0.38 [ 0.25, 0.53 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 77. Age, Total hCG, Free ßhCG, AFP and uE3 at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 77 Age, Total hCG, Free ??hCG, AFP and uE3 at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 7 74 4 426 0.64 [ 0.31, 0.89 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 78. Age, Total hCG, AFP, uE3 and Inhibin A at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 78 Age, Total hCG, AFP, uE3 and Inhibin A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 66 51 16 959 0.80 [ 0.70, 0.88 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 79. Age, Total hCG, AFP, uE3 and Inhibin A at 1:150 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 79 Age, Total hCG, AFP, uE3 and Inhibin A at 1:150 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Debieve 2000 13 8 5 192 0.72 [ 0.47, 0.90 ] 0.96 [ 0.92, 0.98 ]
Palomaki 2006 23 15 9 493 0.72 [ 0.53, 0.86 ] 0.97 [ 0.95, 0.98 ]
Wenstrom 1999 10 199 3 1044 0.77 [ 0.46, 0.95 ] 0.84 [ 0.82, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 80. Age, Total hCG, AFP, uE3 and Inhibin A at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 80 Age, Total hCG, AFP, uE3 and Inhibin A at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Debieve 2000 14 12 4 188 0.78 [ 0.52, 0.94 ] 0.94 [ 0.90, 0.97 ]
Palomaki 2006 23 25 9 483 0.72 [ 0.53, 0.86 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 81. Age, Total hCG, AFP, uE3 and Inhibin A at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 81 Age, Total hCG, AFP, uE3 and Inhibin A at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Debieve 2000 14 12 4 188 0.78 [ 0.52, 0.94 ] 0.94 [ 0.90, 0.97 ]
Malone 2005 74 2988 13 32161 0.85 [ 0.76, 0.92 ] 0.91 [ 0.91, 0.92 ]
Palomaki 2006 23 25 9 483 0.72 [ 0.53, 0.86 ] 0.95 [ 0.93, 0.97 ]
Wald 2003a 66 51 16 959 0.80 [ 0.70, 0.88 ] 0.95 [ 0.93, 0.96 ]
Wenstrom 1999 11 298 2 945 0.85 [ 0.55, 0.98 ] 0.76 [ 0.74, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 82. Age, Total hCG, AFP, uE3 and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 82 Age, Total hCG, AFP, uE3 and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 10 77 1 423 0.91 [ 0.59, 1.00 ] 0.85 [ 0.81, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 83. Age, Total hCG, AFP, uE3 and SP1 at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 83 Age, Total hCG, AFP, uE3 and SP1 at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bartels 1994a 25 16 25 304 0.50 [ 0.36, 0.64 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 84. Age, Free ßhCG, AFP, uE3 and Inhibin A at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 84 Age, Free ??hCG, AFP, uE3 and Inhibin A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 68 51 14 959 0.83 [ 0.73, 0.90 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 85. Age, Free ßhCG, AFP, uE3 and Inhibin A at 1:250 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 85 Age, Free ??hCG, AFP, uE3 and Inhibin A at 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 69 58 13 952 0.84 [ 0.74, 0.91 ] 0.94 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 86. Age, Free ßhCG, AFP, uE3 and Inhibin A at mixed cutpoints.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 86 Age, Free ??hCG, AFP, uE3 and Inhibin A at mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 69 58 13 952 0.84 [ 0.74, 0.91 ] 0.94 [ 0.93, 0.96 ]
Wenstrom 1999 8 236 5 1007 0.62 [ 0.32, 0.86 ] 0.81 [ 0.79, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 87. Age, Total hCG, AFP, uE3, Inhibin A and PAPP-A at 5% FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 87 Age, Total hCG, AFP, uE3, Inhibin A and PAPP-A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 68 51 14 959 0.83 [ 0.73, 0.90 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 88. Age, Total hCG, Free ßhCG, AFP, uE3 and Free αhCG at 1:384 risk.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 88 Age, Total hCG, Free ??hCG, AFP, uE3 and Free ??hCG at 1:384 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Forest 1995 10 71 1 429 0.91 [ 0.59, 1.00 ] 0.86 [ 0.82, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 89. Age, Free ßhCG, AFP, uE3, Inhibin A and PAPP-A at 5%FPR.
Review: Second trimester serum tests for Down’s Syndrome screening
Test: 89 Age, Free ??hCG, AFP, uE3, Inhibin A and PAPP-A at 5%FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003a 69 51 13 959 0.84 [ 0.74, 0.91 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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A D D I T I O N A L T A B L E S
Table 1. Direct comparisons of the diagnostic accuracy of the 12 test strategies
Ratio of
DOR (95%
CI);
P value
(studies)
Free ß hCG
AFP uE3
Inhibin
PAPPA
(quintuple)
Total hCG
AFP uE3
Inhibin
PAPPA
(quintuple)
Total hCG
AFP
Inhibin
(triple)
Total hCG
AFP uE3
Inhibin
(quadru-
ple)
Free ß hCG
AFP uE3
Inhibin
(quadru-
ple)
Free ß hCG
AFP uE3
(triple)
Total hCG
AFP
(double)
Free ß hCG
AFP
(double)
Total hCG
AFP uE3
Inhibin
PAPPA
1.1 (0.4,2.7)
; P=0.85 (K=
1)
Total hCG
AFP
Inhibin
- -
Total hCG
AFP uE3
Inhibin
1.3 (0.5,3.2)
; P=0.58 (K=
1)
1.2 (0.5,2.9)
; P=0.72 (K=
1)
1.
6 (0.2,10.1)
; P=0.64 (K=
1)
Free ß hCG
AFP uE3
Inhibin
1.1 (0.5,2.9)
; P=0.77 (K=
1)
1.0 (0.4,2.6)
; P=0.92 (K=
1)
- 0.8 (0.4,1.7)
; P=0.60
(K=2)
Free ß hCG
AFP uE3
1.8 (0.7,4.4)
; P=0.19 (K=
1)
1.6 (0.7,4.0)
; P=0.26 (K=
1)
- 1.4 (0.6,3.3)
; P=0.44 (K=
1)
1.6 (0.7,3.8)
; P=0.31 (K=
1)
Total hCG
AFP
2.8 (1.2,6.4)
; P=0.02 (K=
1)
2.5 (1.1,5.8)
; P=0.03 (K=
1)
4.
4 (0.8,25.7)
; P=0.10 (K=
1)
2.3 (1.1,4.7)
; P=0.03 (K=
2)
2.4 (1.0,5.6)
; P=0.04 (K=
1)
1.2 (0.7,1.9)
; P=0.56 (K=
3)
Free ß hCG
AFP
2.2 (0.9,5.2)
; P=0.07 (K=
1)
2.0 (0.9,4.7)
; P=0.11 (K=
1)
1.7 (0.7,3.9)
; P=0.21 (K=
1)
1.9 (0.8,4.5)
; P=0.14 (K=
1)
1.2 (0.8,1.9)
; P=0.34 (K=
5)
1.0 (0.6,1.6)
; P=0.91 (K=
4)
Total hCG
AFP uE3
1.8 (0.8,4.4)
; P=0.17 (K=
1)
1.7 (0.7,3.9)
; P=0.24 (K=
1)
2.
0 (0.3,12.7)
; P=0.47 (K=
1)
1.2 (0.6,2.3)
; P=0.55 (K=
3)
1.6 (0.8,3.2)
; P=0.22 (K=
2)
1.0 (0.7,1.6)
; P=0.93 (K=
6)
0.9 (0.6,1.3)
; P=0.66 (K=
6)
0.9 (0.6,1.4)
; P=0.56 (K=
5)
Free ß hCG 3.4 (1.5,7.9)
; P=0.004
(K=1)
3.1 (1.4,7.1)
; P=0.007
(K=1)
- 2.6 (1.2,5.9)
; P=0.02 (K=
1)
3.0 (1.3,6.8)
; P=0.01 (K=
1)
2.0 (1.2,3.3)
; P=0.008
(K=3)
1.7 (1.0,2.8)
; P=0.04 (K=
3)
1.5 (1.0,2.3)
; P=0.06 (K=
4)
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Table 1. Direct comparisons of the diagnostic accuracy of the 12 test strategies (Continued)
Total hCG 4.8 (2.1,11.
1); P=0.
0002 (K=1)
4.4 (1.9,10.
0); P=0.
0004 (K=1)
- 3.7 (1.7,8.4)
; P=0.001
(K=1)
4.2 (1.8,9.6)
; P=0.0007
(K=1)
2.2 (1.3,3.6)
; P=0.003
(K=3)
1.9 (1.1,3.1)
; P=0.01 (K=
3)
1.8 (1.1,3.0)
; P=0.02 (K=
3)
AFP 7.5 (3.2,
17.3); P=<0.
0001 (K=1)
6.9 (3.0,15.
7); P<0.
0001 (K=1)
- 5.8 (2.6,13.
1); P<0.
0001 (K=1)
6.5 (2.8,15.
1); P<0.
0001 (K=1)
3.1 (1.5,6.2)
; P=0.002
(K=2)
2.2 (1.2,4.4)
; P=0.02 (K=
2)
2.7 (1.6,4.5)
; P=0.0001
(K=3)
Ratio of
DOR (95%
CI); P-
value (stud-
ies)
Total hCG
AFP uE3
(triple)
Free ß hCG
(single)
Total hCG
(single)
Free ß hCG 2.0 (1.2,3.4)
; P=0.005
(K=3)
Total hCG 2.2 (1.4,3.7)
; P=0.002
(K=3)
1.1 (0.7,1.8)
; P=0.70 (K=
3)
AFP 2.9 (1.5,5.8)
; P=0.002
(K=2)
1.9 (1.1,3.0)
; P=0.01 (K=
3)
1.1 (0.6,2.1)
; P=0.81 (K=
2)
Direct comparisons are made only using data from studies which compare each pair of tests on the same women. Relative DOR are
computed by division of the DOR for the column by the DOR for the row. If the relative DOR is greater than one then the
diagnostic accuracy of the test for the column is higher than that for the row, if less than one the diagnostic accuracy of the test in
the row is higher than in the column. All test combinations include maternal age. - indicates that no comparative study is available.
Table 2. Indirect comparisons of the diagnostic accuracy of the 12 test strategies
Ratio of
DOR
(95% CI);
P value
Free
ßhCG
AFP uE3
Inhibin
PAPPA
(quintu-
ple)
Total hCG
AFP uE3
Inhibin
PAPPA
(quintu-
ple)
Total hCG
AFP
Inhibin
(triple)
Total hCG
AFP uE3
Inhibin
(quadru-
ple)
Free ß
hCG AFP
uE3
Inhibin
(quadru-
ple)
Free ß
hCG AFP
uE3
(triple)
Total hCG
AFP
(double)
Free ß
hCG AFP
(double)
DOR
(95% CI)
Studies
88 (35,
224) k=1
80 (32,
201) k=1
71 (23,
220) k=2
50 (30,84)
k=5
41 (18,94)
k=2
34 (21,53)
k=7
27 (19,39)
k=15
26 (18,38)
k=12
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Table 2. Indirect comparisons of the diagnostic accuracy of the 12 test strategies (Continued)
Total hCG
AFP uE3
Inhibin
PAPPA
80 (32,
201) k=1
1.1 (0.3,4.
1); P=0.87
Total hCG
AFP
Inhibin
71 (23,
220) k=2
1.2 (0.3,5.
3); P=0.77
1.1 (0.3,4.
8); P=0.88
Total hCG
AFP uE3
Inhibin
50 (30,84)
k=5
1.8 (0.6,5.
1); P=0.29
1.6 (0.6,4.
6); P=0.39
1.4 (0.4,4.
9); P=0.58
Free ß
hCG AFP
uE3
Inhibin
41 (18,84)
k=2
2.1 (0.6,7.
4); P=0.23
1.9 (0.6,6.
7); P=0.30
1.7 (0.4,7.
0); P=0.44
1.2 (0.5,3.
2); P=0.69
Free ß
hCG AFP
uE3
34 (21,53)
k=7
2.6 (0.9,7.
4); P=0.06
2.4 (0.9,6.
6); P=0.10
2.1 (0.6,7.
2); P=0.23
1.5 (0.8,2.
9); P=0.24
1.2 (0.5,3.
2); P=0.67
Total hCG
AFP
27 (19,39)
k=15
3.3 (1.2,8.
7); P=0.02
2.9 (1.1,7.
8); P=0.03
2.6 (0.8,8.
6); P=0.11
1.8 (1.0,3.
4); P=0.05
1.5 (0.6,3.
7); P=0.37
1.2 (0.7,2.
1); P=0.43
Free ß
hCG AFP
26 (18,38)
k=12
3.4 (1.3,9.
3); P=0.01
3.1 (1.2,8.
3); P=0.03
2.8 (0.8,9.
1); P=0.09
1.9 (1.0,3.
6); P=0.04
1.6 (0.6,4.
0); P=0.31
1.3 (0.7,2.
3); P=0.35
1.1 (0.7,1.
7); P=0.81
Total hCG
AFP uE3
21 (16,28)
k=24
4.3 (1.6,
11.2); P=0.
003
3.8 (1.5,
10.0); P=0.
006
3.4 (1.1,
11.0); P=0.
04
2.
4 (1.4,4.3)
; P=0.003
2.0 (0.8,4.
7); P=0.12
1.6 (1.0,2.
7); P=0.06
1.3 (0.9,1.
9); P=0.18
1.2 (0.8,1.
9); P=0.33
Free ß
hCG
14 (8,24)
k=4
6.4 (2.2,
18.5); P=0.
0005
5.8 (2.0,
16.6); P=0.
001
5.2 (1.5,
18.2); P=0.
01
3.
6 (1.8,7.5)
; P=0.0004
3.0 (1.1,8.
0); P=0.03
2.
4 (1.3,4.7)
; P=0.007
2.0 (1.1,3.
5); P=0.02
1.9 (1.0,3.
4); P=0.04
Total hCG 12 (8,20)
k=4
7.3 (2.6,
20.4); P=0.
0002
6.6 (2.3,
18.4); P=0.
0004
5.9 (1.7,
20.1); P=0.
005
4.
1 (2.1,8.2)
; P<0.0001
3.4 (1.3,8.
7); P=0.01
2.
8 (1.5,5.2)
; P=0.001
2.
2 (1.3,3.8)
; P=0.003
2.
1 (1.2,3.7)
; P=0.009
AFP 8 (5,14) k=
4
10.8 (3.7,
31.4); P=
<0.0001
9.7 (3.3,
28.1) P<0.
0001
8.6 (2.4,
30.6); P=0.
0008
6.1 (2.9,
12.8); P<0.
0001
5.0 (1.8,
13.5); P=0.
002
4.
1 (2.1,8.0)
P<0.0001
3.
3 (1.8,6.0)
P<0.0001
3.
1 (1.7,5.8)
P=0.0003
Ratio of
DOR
(95%CI);
P-value
Total hCG
AFP uE3
(triple)
Free
ßhCG
(single)
Total hCG
(single)
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Table 2. Indirect comparisons of the diagnostic accuracy of the 12 test strategies (Continued)
DOR
(95%CI)
Studies
21 (16,28)
k=24
14 (8,24)
k=4
12 (8,20)
k=4
Free ß
hCG
14 (8,24)
k=4
1.5 (0.9,2.
6); P=0.14
Total hCG 12 (8,20)
k=4
1.7 (1.0,2.
9); P=0.04
1.1 (0.6,2.
2); P=0.71
AFP 8 (5,14) k=
4
2.
5 (1.4,4.5)
; P=0.002
1.7 (0.8,3.
4); P=0.15
1.5 (0.8,2.
9); P=0.26
Indirect comparisons are made using all available data. Relative DORs are computed by division of the DOR for the test in the column
by the DOR for the test in the row. If the relative DOR is greater than one then the diagnostic accuracy of the test for the column
is higher than that for the row, if less than one the diagnostic accuracy of the test in the row is higher than in the column. All test
combinations include maternal age.
Table 3. Investigation of sources of heterogeneity
Test combination Relative DOR (95%
CI)
P value Sensitivity at 5% FPR (95% CI) (studies)
Effect of maternal age <= 35 years > 35 years
Free β hCG, AFP and
age
0.56 (0.33, 0.96) P=0.03 66.4 (58.8, 73.2) k=9 51.7 (39.1, 64.1) k=3
Total hCG, AFP, uE3
and age
0.43 (0.29, 0.63) P< 0.0001 68.6 (62.3, 74.3) k=11 48.4 (40.7, 56.2) k=13
Total hCG, AFP and age 0.41 (0.12, 1.38) P=0.15 69.1 (64.1, 73.7) k=13 54.2 (44.1, 64.1) k=2
Bias in both ﬁtting and evaluating in derivation datasets Derivation dataset Validation dataset
Free β hCG, AFP and
age
0.67 (0.40, 1.09) P=0.11 67.0 (58.9, 74.5) k=6 57.2 (47.1, 66.6) k= 6
Total hCG, AFP, uE3
and age
1.48 (0.86, 2.56) P=0.15 54.0 (43.2, 64.4) k=8 63.0 (54.6, 70.6) k=16
Total hCG, AFP and age 0.99 (0.64,1.52) P=0.95 66.1 (59.2, 72.3) k=6 65.8 (59.3, 71.7) k=9
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Table 4. Sensitivity analysis of maternal age effect
Correc-
tion made
for miss-
ing false
negatives
in studies
with de-
layed veri-
ﬁcation of
test nega-
tives
Free β hCG, AFP and age Total hCG, AFP, uE3 and age Total hCG, AFP and age
Relative
DOR
(P value)
Sensitivity(%) at
5%FPR
Relative
DOR
(P value)
Sensitivity(%) at
5%FPR
Relative
DOR
(P value)
Sensitivity(%) at
5%FPR
> 35yrs
(n = 3)
<= 35yrs
( n= 9)
> 35 yrs
(n = 13)
<= 35 yrs
(n = 11)
> 35yrs
(n = 2)
<= 35yrs
(n = 13)
No FN
correction
ROR=0.
56
(P=0.03)
51.7% 66.4% ROR = 0.
43
(P < 0.
0001)
48.4% 68.6% ROR=0.
41
(P=0.15)
54.2% 69.1%
FN
increased
+10%
ROR = 0.
61
(P=0.07)
51.7% 64.4% ROR = 0.
46
(P < 0.
0001)
48.0% 66.4% ROR=0.
45
(P=0.14)
53.1% 67.1%
FN
increased
+20%
ROR = 0.
66
(P=0.11)
51.6% 62.5% ROR = 0.
50
(P < 0.
0001)
47.6% 64.4% ROR=0.
49
(P=0.14)
52.1% 65.3%
FN
increased
+30%
ROR=0.
71
(P=0.18)
51.5% 60.7% ROR = 0.
54
(P < 0.
0001)
47.2% 62.5% ROR=0.
53
(P=0.15)
51.1% 63.5%
FN
increased
+40%
ROR=0.
75
(P=0.27)
51.5% 59.0% ROR = 0.
57
(P < 0.
0001)
46.8% 60.7% ROR=0.
57
(P=0.16)
50.3% 61.8%
FN
increased
+50%
ROR=0.
80
(P=0.39)
51.4% 57.4% ROR = 0.
61
(P = 0.01)
46.5% 59.0% ROR=0.
61
(P=0.18)
49.6% 60.2%
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A P P E N D I C E S
Appendix 1. Search Strategy
Database: Ovid MEDLINE
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 speciﬁc$.mp.
38 diagnos$.ti,ab.
39 “reproducibility of results”.mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.
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48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
*******************************************************
EMBASE via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER OR MARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
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40. REFERENCE ADJ VALUE$
41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ ’21’
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCYOR PREGNANTOR TRIMESTER$ ORMATERNAL OR FETUS
OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 24 OR
25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 37 OR 38 OR 39 OR 40 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
*******************************************************
CINAHL via OVID
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 “area under curve”.mp.
31 exp false negative reactions/ or exp false positive reactions/
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32 (false positive$ or false negative$).mp.
33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 speciﬁc$.mp.
36 diagnos$.ti,ab.
37 “reproducibility of results”.mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
*******************************************************
Search terms and instructions for Biosis
The following search terms were entered separately in standard search box (select ‘Titles/subject/abstract’ from the drop-down box on
the right of the search box).
1. “reference standard*”
2. “reference value*”
3. “reproducibility of results”
4. diagnos*
5. sensitiv*
6. speciﬁc*
7. “likelihood ratio*”
8. “false negative*
9. “false positive”
10. “area under curve”
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. “ductus venosus”
19. “nasal bone”
20. “tricuspid regurgitation”
21. “chorion* vill* sampling”
22. amniocentesis
23. ultrasound
24. inhibin*
25. “unconjugaed oestriol”
26. “unconjugated estriol”
27. afp
28. “alpha fetoprotein*”
29. alphafetoprotein*
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30. “ bhcg”
31. “human chorionic gonadotrophin”
32. “papp a”
33. “pregnancy associated plasma protein”
34. “nuchal translucency”
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. “trisomy 21”
44. mosaicism
45. “down* syndrome”
The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: “trisomy 21”) or (al: (mosaicism))) or (al: “down* syndrome”))) and (((((((((((((((((((((((((((((((((((al: “reference stan-
dard*”) or (al: “reference value*”)) or (al: “reproducibility of results”)) or (al: (diagnos*))) or (al: (speciﬁc*))) or (al: (sensitiv*)))
or (al: “likelihood ratio*”)) or (al: “false negative*”)) or (al: “false positive*”)) or (al: “area under curve”)) or (al: (auc))) or (al:
(roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: “ductus venosus”))
or (al: “tricuspid regurgitation”)) or (al: “nasal bone”)) or (al: “chorion* vill* sampling”)) or (al: (amniocentesis))) or (al:
(ultrasound))) or (al: (inhibin*))) or (al: “unconjugated oestriol”)) or (al: “unconjugated estriol”)) or (al: (afp))) or (al: “alpha
feto protein*”)) or (al: “alpha fetoprotein*”)) or (al: “b hcg”)) or (al: “human chorionic gonadotropin”)) or (al: “papp a”))
or (al: “pregnancy associated plasma protein”)) or (al: “nuchal translucency”)))) and (((((((((al: (foetal)) or (al: (fetal))) or (al:
(foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))
*******************************************************
The Database of Abstracts of Reviews of Effectiveness (DARE), National Research Register and Health Services Research Projects in
Progress database
:
1. Down syndrome (MeSH)
2. down* next syndrome
3. trisomy
4. aneuploidy
5. mosaicism
6. OR/ 1-5
*******************************************************
MEDION (http://www.mediondatabase.nl/)
ICPC code for pregnancy - ‘W’.
*******************************************************
The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine - download the database to a .pdf ﬁle and search for
the following terms separately:
Down
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Trisomy
Aneuploidy
Pregnant
Pregnancy
Pregnancies
Mosaicism
*******************************************************
Appendix 2. Glossary of terms (adapted in part from the UK National Screening Committee
Glossary)
Abnormal ductus venosus ﬂow velocity The ductus venosus is a vessel in the fetus which allows oxygenated blood from the placenta
to bypass the fetal liver andﬂow straight to the heart. In conditions such asDown’s syndrome
the pressure in this vessel can be abnormally high
Absent nasal bone Absence of the bone that forms the bridge of the nose, which may be detected at ultrasound
scan during early pregnancy
Affected individuals Those individuals who are affected by the disorder for which they are being screened
Amniocentesis Amniocentesis is an invasive procedure which involves taking a small sample of the amniotic
ﬂuid (liquor) surrounding the baby, using a needle which goes through the abdominal wall
into the uterus, and is usually performed after 15 weeks gestation
Chorionic villus sampling (CVS) Chorionic villus sampling involves taking a sample of the placental tissue using a needle
which goes through the abdominal wall and uterus or a cannula through the cervix. It is
usually performed between 10 and 13 weeks gestation
Combined test First trimester test (up to 13 + 6 weeks of pregnancy) based on combining nuchal translu-
cency measurement with free beta-hCG, pregnancy-associated plasma protein A (PAPP-A)
and the woman’s age
Diagnostic accuracy The amount of agreement between the information from the index test and the reference
standard (see below)
Diagnostic test A deﬁnitive test, performed after a positive screening test result that gives a diagnosis (i.e.
yes or no)?
Double test Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on themeasurement
of alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG ß either free beta-hCG
or total hCG), together with the woman’s age
First trimester Pregnancy from conception up to 13 weeks and 6 days.
Iatrogenic A disease or condition in a patient occurring as a result of treatment
Index test A test or group of tests being evaluated in a systematic review
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(Continued)
Integrated test Measurements performed at different times of pregnancy combined into a single test result.
Unless otherwise speciﬁed, ’integrated test’ refers to the combination of nuchal translucency
measurement and PAPP-A in the ﬁrst trimester, with the quadruple test (see below) in the
second
Mosaicism This is a condition in which person has some cells containing a normal number of chro-
mosomes, and some containing an abnormal number. The more abnormal cells there are,
the greater the effect
Multiple of the median (MOM) The serum test concentration for a pregnant woman divided by the average (median) for
unaffected pregnancies in a deﬁned population at the same stage of pregnancy
Quadruple test Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on themeasurement
of AFP, uE3, free beta-hCG (or total hCG), and inhibin-A together with the woman’s age
Reference Standard The best available method for establishing the presence or absence of the target disease or
condition
Second trimester Pregnancy from14weeks to 28weeks gestation.Note that for the purposes of this Cochrane
review, second trimester testing refers to the period of 14 to 24 weeks gestation
Tricuspid regurgitation Leakiness of or backﬂow of blood through the tricuspid valve of the heart. The tricuspid
valve separates the upper and lower chambers of the right side of the heart
Triple test Second trimester test (from 14 up to 24 weeks of pregnancy) based on the measurement of
AFP, unconjugated oestriol (uE3), and hCG (either total hCG or free beta-hCG) together
with the woman’s age
Trisomy The presence of an extra chromosome resulting in three copies of a particular chromosome
instead of the normal two
Translocation Part of one chromosome is broken off and attached to another chromosome. This does not
usually cause the individual any problems as they have a normal amount of chromosomes,
but in an abnormal arrangement. It can be passed on as an extra chromosome to offspring,
resulting in conditions such as Down’s syndrome
H I S T O R Y
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JP applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the ﬁnal draft of the review.
ZA applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the ﬁnal draft of the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test
accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies, and where
such information was found it was difﬁcult to extract meaningful data to allow for comparison between studies, as data were not
reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported
at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects
of test; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to
invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to deﬁnitive testing or in
a karyotypically normal pregnancy and following conﬁrmation of Down’s Syndrome or following detection of other chromosomal
abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of deﬁnitive testing by women.
The following reﬁnements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high.
We excluded studies that identiﬁed fewer than ﬁve Down’s syndrome pregnancies in their study population. We excluded studies that
had less than 80% follow-up of participants.
In addition, the analytical strategy was informed by the volume of tests and studies included, and developed so that we focused on key
tests and test combinations by a) only meta-analysed tests that were included in four or more papers or b) showed more than 70%
sensitivity for more than 90% speciﬁcity. In addition a requirement that a minimum of 10 studies for a single test was required before
subgroup analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.
206Second trimester serum tests for Down’s Syndrome screening (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
N O T E S
This review belongs to a suite of reviews examining antenatal screening for Down’s syndrome which include four other titles: ’First
trimester serum tests for Down’s syndrome screening’; ’First trimester serum and ultrasound tests for Down’s syndrome screening’; ’First and
second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening’; and ’Urine tests for Down’s
syndrome screening’. The project as a whole has beenmuch larger than initially anticipated, both in terms of size and statistical complexity.
The initial search was completed in 2007. After identifying studies appropriate for inclusion, a signiﬁcant amount of time has been
devoted to data management and analysis.
The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new
second trimester serum tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to
tests included in this review. The literature search has recently been updated and work is in progress with the other reviews in this suite,
to bring these reviews up to date prior to publication. Following publication of the other reviews in this suite, we plan to update this
review and then prepare an umbrella review, examining the overall best performing test combinations for antenatal Down’s syndrome
screening.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Biological Markers [∗blood]; Down Syndrome [∗diagnosis]; Maternal Age; Pregnancy Trimester, Second [blood]; Prenatal Diagnosis
[∗methods]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans; Pregnancy
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